US 7,863,419 B2Grant
Antibodies having altered effector function and methods for making the same
Issue Date:2011-01-04
•88 Claims
•15 Drawing Sheets
Abstract
The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
Metadata
Assignee
- Biogen Idec MA Inc.
Inventors
- Frederick R. Taylor
- Ellen Garber
Application Information
Application Number:US 11/360,938
Filing Date:2006-02-22
Priority Date:2003-08-22
Art Unit:1644
Classifications
IPC:
C07K16/00C07K16/46
Patent Drawings (15 sheets)
Description
RELATED INFORMATION
[0001] The application is a continuation of co-pending International Application No. PCT/US2004/027476, filed Aug. 23, 2004, which, in turn, claims priority to U.S. provisional patent application No. 60/497,193, filed on Aug. 22, 2003. The entire contents of the above-identified applications are hereby incorporated by reference in their entirety.
[0002] The contents of any patents, patent applications, and references cited throughout this specification are hereby incorporated by reference in their entireties.
BACKGROUND OF THE INVENTION
[0003] The immune response is a mechanism by which the body defends itself against foreign substances that invade it, causing infection or disease. This mechanism is based on the ability of antibodies produced or administered to the host to bind the antigen though its variable region. Once the antigen is bound by the antibody, the antigen is targeted for destruction, often mediated in part, by the constant region or Fc domain of the antibody.
[0004] For example, one activity of the Fc domain of the antibody is to bind complement proteins which can assist in lysing the target antigen, for example, a cellular pathogen. Another activity of the Fc region is to bind to Fc receptors (FcR) on the surface of immune cells, or so-called effector cells, which have the ability to trigger other immune effects. These immune effects include, for example, release of immune activators, regulation of antibody production, endocytosis, phagocytosis, and cell killing. In some clinical applications these responses are crucial for the efficacy of the antibody while in other cases they provoke unwanted side effects. One example of an effector-mediated side effect is the release of inflammatory cytokines causing an acute fever reaction. Another example is the long term deletion of antigen-bearing cells.
[0005] The effector function of an antibody can be avoided by using antibody fragments lacking the Fc region (e.g., such as a Fab, Fab′2, or single chain antibody (sFv)) however these fragments have a reduced half-life, only one antigen binding site instead of two (e.g., in the case of Fab antibody fragments and single chain antibodies (sFv)), and are more difficult to purify.
[0006] Currently there are limited ways to reduce the effector function of an antibody while retaining the other valuable attributes of the Fc region. One approach is to mutate amino acids on the surface of the antibody that are involved in the effector binding interactions. While some mutations lead to a reduction of effector function, residual activity usually remains. Moreover, these added mutations can make the antibody immunogenic.
[0007] Another approach to reduce effector function is to remove sugars that are linked to particular residues in the Fc region, by for example, deleting or altering the residue the sugar is attached to, removing the sugars enzymatically, by producing the antibody in cells cultured in the presence of a glycosylation inhibitor, or by expressing the antibody in cells unable to glycosylate proteins. However, the forgoing approaches leave residual effector function both in the form of complement-dependent cytolytic activity and Fc receptor binding. Thus, a further decrease in effector function would be important to guarantee complete ablation of activity.
[0008] Accordingly, a need exists for an improved method of making aglycosylated antibodies with altered or reduced effector function.
SUMMARY OF THE INVENTION
[0009] The invention solves the foregoing problems of glycosylated antibodies, indeed of any Fc-containing protein, by providing improved methods for producing aglycosylated antigen binding proteins, for example, aglycosylated antibodies, more specifically, aglycosylated IgG antibodies, by introducing only minimal alterations. In particular, the invention provides a method for introducing an amino acid alteration at a first amino acid residue position which results in the reduced glycosylation of the polypeptide at a different or second amino acid residue position. The first amino acid can be modified to comprise a desirable side chain chemistry such that it can be linked, for example, to an additional functional moiety, such as a blocking moiety, detectable moiety, diagnostic moiety, or therapeutic moiety. The resulting aglycosylated antigen binding polypeptides, for example, aglycosylated IgG antibody has, for example, altered or reduced effector function. The decrease in undesired effector function provided by the polypeptides and methods of the invention was surprisingly more substantial than other conventional means of aglycosylating Fc regions.
[0010] Accordingly, the invention has several advantages which include, but are not limited to, the following:
-
- [0011] providing aglycosylated antigen binding polypeptides, for example, aglycosylated IgG antibodies, suitable as therapeutics because of their reduced effector function;
- [0012] an efficient method of producing aglycosylated antibodies with minimal alterations to the polypeptide;
- [0013] an efficient method of producing aglycosylated antibodies while also providing a site for linking a desirable functional moiety, such as a blocking moiety, detectable moiety, diagnostic moiety, or therapeutic moiety;
- [0014] a method of altering the effector function of an antibody while avoiding any increase in immunogenicity; and
- [0015] methods for treating a subject in need of an aglycosylated antigen binding polypeptide therapy.
[0016] Accordingly, in one aspect, the invention provides a polypeptide, or variant polypeptide, containing an Fc region, wherein the Fc region has a modified first amino acid residue having a preferred side chain chemistry, and a second amino acid residue having reduced glycosylation as compared to an unmodified polypeptide or parent polypeptide.
[0017] In certain embodiments, the side chain chemistry of the first amino acid residue can be linked, for example, covalently linked, to an additional moiety, i.e., a functional moiety such as, for example, a blocking moiety, detectable moiety, diagnostic moiety, and/or therapeutic moiety.
[0018] In one embodiment, the functional moiety is a blocking moiety, in that the moiety inhibits or blocks glycosylation of the polypeptide at the second amino acid residue. The blocking moiety can also function to block effector function, for example, by inhibiting the binding of the Fc region of the polypeptide to an Fc receptor or complement protein.
[0019] In a preferred embodiment, the blocking moiety is a cysteine adduct which forms when the first amino acid residue is a cysteine or has a side chain chemistry comprising a thiol.
[0020] In certain embodiments, the first amino acid comprises a cysteine, cysteine adduct, cystine, mixed disulfide adduct, or disulfide linkage.
[0021] In another preferred embodiment, the blocking moiety is a polyalkylene glycol moiety, for example, a PEG moiety and preferably a PEG-maleimide moiety.
[0022] In a related embodiment, to the first amino acid of the polypeptide is a cysteine or has a side chain chemistry comprising a thiol and the PEG moiety is attached thereto.
[0023] In certain embodiments, the cysteine or thiol side chain chemistry is reduced to remove such cysteine adduct, cystine, mixed disulfide adduct, or disulfide linkage, and the PEG moiety is subsequently attached to the cysteine residue or thiol side chain.
[0024] In another embodiment, the functional moiety is a detectable moiety, such as, but not limited to, a fluorescent moiety or isotopic moiety.
[0025] In another embodiment, the functional moiety is a diagnostic moiety, which is a moiety capable of revealing the presence of a disease or disorder.
[0026] In another embodiment, the functional moiety is a therapeutic moiety such as, but not limited to, an anti-inflammatory agent, anti-cancer agent, anti-neurodegenerative agent, or anti-infective agent.
[0027] In another aspect, the variant polypeptide of a parent polypeptide comprises an Fc region with a modified first amino acid residue, wherein the modified first amino acid is spatially positioned such that reduced glycosylation at a second amino acid is achieved. In a preferred embodiment, the variant polypeptide, which is aglycosylated, also has reduced effector function, as compared to the parent polypeptide.
[0028] In a related embodiment, the modified first amino acid is spatially positioned from the second amino acid by an interval of at least 1 amino acid position or more, for example, by about 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residue positions or more.
[0029] In one embodiment, the modified first amino acid residue has a preferred side chain chemistry. In a related embodiment, the preferred side chain chemistry is of sufficient steric bulk and/or charge such that the polypeptide displays reduced glycosylation and/or effector function.
[0030] In one embodiment, the reduced effector function is reduced binding to an Fc receptor (FcR), such as FcγRI, FcγRII, FcγRIII, and/or FcγRIIIb.
[0031] In another embodiment, the reduced effector function is reduced binding to a complement protein, such as C1q.
[0032] In a related embodiment, the reduced binding is by a factor of about 1-fold to about 15-fold or more.
[0033] In another embodiment, the polypeptide has a first amino acid residue and second amino acid residue that are near or within a glycosylation motif, for example, an N-linked glycosylation motif that contains the amino acid sequence NXT or NXS. In a particular embodiment, the polypeptide of the method has a first amino acid residue modified by an amino acid substitution. In a related embodiment, the first amino acid residue is amino acid 299 and the second amino acid residue is amino acid 297, according to the Kabat numbering.
[0034] In another embodiment, the amino acid substitution is selected from the group consisting of T299A, T299N, T299G, T299Y, T299C, T299H, T299E, T299D, T299K, T299R, T299G, T2991, T299L, T299M, T299F, T299P, T299W, and T299V according to the Kabat numbering.
[0035] In a particular embodiment, the amino acid substitution is T299C or T299A.
[0036] In another embodiment, the polypeptide of the invention is pegylated at the modified first amino acid residue, for example, a cysteine residue, and in particular, with PEG-maleimide.
[0037] In a preferred embodiment, the polypeptide is an antibody, for example, an antibody having an Fc region obtained from an antibody such as IgG1, IgG2, IgG3, or IgG4, and preferably, IgG1 or IgG4.
[0038] In yet another embodiment, the foregoing polypeptide displays altered effector function, for example, reduced binding to an Fc receptor (FcR) (such as FcγRI, FcγRII, or FcγRIII) or reduced binding to a complement protein, such as C1q.
[0039] In another embodiment, the forgoing polypeptide binds to an antigen such as a ligand, cytokine, receptor, cell surface antigen, or cancer cell antigen.
[0040] In another embodiment, the foregoing polypeptide is in a suitable pharmaceutical carrier.
[0041] In a another aspect, the invention provides an isolated nucleic acid encoding any one of the foregoing polypeptides, wherein the nucleic acid can be encoded in a vector, such that, for example, the nucleic acid or vector encoding the same can be expressed in a host cell.
[0042] In a another aspect, the invention provides a method for producing an antigen binding polypeptide by culturing the foregoing host cell containing a nucleic acid encoding a polypeptide of the invention under suitable culture conditions for producing the polypeptide followed by, for example, recovering the polypeptide from the host cell culture.
[0043] In a another aspect, the invention provides a method of producing a modified antigen binding polypeptide having reduced glycosylation in an Fc region, by identifying an original first amino acid residue in an original polypeptide and a second amino acid residue capable of being glycosylated in an Fc region of the original polypeptide, and modifying the original first amino acid residue in the original polypeptide to produce a modified first amino acid in a modified polypeptide, such that glycosylation of the second amino acid residue of the Fc region is decreased in the modified or variant polypeptide as compared to the original or parent polypeptide.
[0044] In one embodiment, the method can comprise the step of determining if the modified antigen binding polypeptide displays altered effector function.
[0045] In another aspect, the invention provides a method of reducing effector function by identifying a first amino acid residue in the antibody, which when modified, is capable of altering the glycosylation of the second amino acid residue in the Fc region of the antibody. The identifying of the first amino acid residue to be modified can be computer-assisted using, for example, art recognized modeling software. The first amino acid residue is then modified such that glycosylation of the second amino acid residue of the Fc region is reduced in the modified antibody as compared to the unmodified parent antibody.
[0046] In another aspect, the invention provides a polypeptide produced by any one of the foregoing methods.
[0047] In another aspect, the invention provides a method of diagnosing, treating, or preventing a disease or disorder in an animal, for example, a human patient, by administering a polypeptide of the invention having reduced glycosylation and/or effector function.
[0048] Other features and advantages of the invention will be apparent from the following detailed description and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0049] FIG. 1 depicts the structure of a typical antigen binding polypeptide (IgG antibody) and the functional properties of antigen binding and effector function (e.g., Fc receptor (FcR) binding) of an antibody. Also shown is how the presence of sugars (glycosylation) in the CH2 domain of the antibody alters effector function (FcR binding) but does not affect antigen binding.
[0050] FIG. 2 depicts the structure and sequence of an Fc region of an antibody of the invention where a residue proximal to the glycosylated amino acid reside can be altered to inhibit glycosylation (left panel). Also shown (right panel) is that if the first amino acid reside is a cysteine, glycosylation is not only inhibited but the cysteine residue provides a site for linking a functional moiety, e.g., a blocking moiety, such as a cysteine adduct or pegylation moiety (shown) or other functional moieties (not shown).
[0051] FIG. 3 depicts a digital image of SDS-PAGE analysis of glycosylated antibodies and aglycosylated antibody IgG1 variants under non-reducing conditions (lanes 1-5) and reducing conditions (lanes 7-11). The aglycosylated antibody variants (or Fc regions thereof) migrate faster than glycosylated controls because they lack the added sugar moieties (compare lanes 3-5 with lane 2 and lanes 9-11 with lane 8). In particular, lane 1 contains a control full length antibody (monoclonal IgG1), lane 2 contains a control wild type (glycosylated) Fc region (IgG1), lane 3 contains an aglycosylated Fc variant (N297Q human IgG1), lane 4 contains an aglycosylated Fc variant (T299A human IgG1), lane 5 contains an aglycosylated Fc variant (T299C human IgG1), lane 6 contains molecular weight standards, lane 7 contains a control full length antibody (monoclonal IgG1), lane 8, contains a control wild type (glycosylated) Fc region (IgG1), lane 9 contains an aglycosylated Fc variant (N297Q human IgG1), lane 10 contains an aglycosylated Fc variant (T299A human IgG1), and lane 11 contains an aglycosylated Fc variant (T299C human IgG1).
[0052] FIG. 4 depicts a digital image of SDS-PAGE analysis of glycosylated antibodies and aglycosyl antibody IgG4 variants under non-reducing conditions (lanes 1-3) and reducing conditions (lanes 5-7). The IgG4 aglycosyl antibody variant migrates faster than the glycosylated control because it lacks the added sugar moieties (compare lane 3 with lane 2 and lane 7 with lane 6). In particular, lanes 1 and 5 contain a control IgG1, lanes 2 and 6 contain a control IgG4 antibody, and lanes 3 and 7 contain the IgG4 aglycosyl variant (T299A). Lane 4 contains molecular weight standards.
[0053] FIG. 5 depicts a digital image of SDS-PAGE analysis of aglycosylated antibody variants (Fc regions) under non-reducing conditions showing that cysteines are blocked in the presence (lanes 3, 4, 8, and 9) or absence (lanes 1, 2, 6, and 7) of peg-maleimide. In particular, lanes 1-4 contain T299C and lanes 6-9 contain T299A, with molecular weight standards in lane 10.
[0054] FIG. 6 depicts a digital image of SDS-PAGE analysis of aglycosylated antibody variants (Fc regions) under reducing conditions showing that introduced cysteines (T299C) are pegylated but alanine resides (T299A) are not, as evidenced by reduced mobility. In particular, lanes 1-2 were loaded with increasing amounts (2.5 ug, 7.5 ug) of Fc T299C, lanes 3-4 were loaded with pegylated Fc T299C, lanes 5-6 were loaded with increasing amounts of Fc T299A, lanes 7-8 were loaded with pegylated Fc T299A, and lane 9 was loaded with a protein molecular weight marker.
[0055] FIG. 7 depicts a digital image of SDS-PAGE analysis of the pegylation of the antibody variant T299C (Fc region) as compared to antibody variant T299A (Fc region) under non-reducing and non-denaturing conditions after first reducing the test proteins with TCEP to remove the cysteine adduct followed by pegylation showing that the introduced cysteines (T299C) are pegylated but alanine resides (T299A) are not, as evidenced by reduced mobility. In particular, lane 1 was loaded with Fc T299A after reduction and reoxidation, non-reducing gel conditions, lane 2 with Fc T299C after reduction and reoxidation, non-reducing gel conditions, lane 3 with a protein molecular weight marker, lane 4 Fc T299A with no peg-maleimide, reducing gel conditions, lane 5 Fc T299C no peg-maleimide, reducing gel conditions, lane 6 Fc T299A plus peg-maleimide, reducing gel conditions, and lane 7 with Fc T299C plus peg-maleimide, reducing gel conditions.
[0056] FIGS. 8-11 show mass spectroscopy histogram analyses of aglycosylated antibody variants having cysteine (T299C) or alanine (T299A) mutations under reducing and non-reducing conditions. The mass spectroscopy data shows that under non-reducing conditions the T299C antibody variant has added mass due to the formation of a cysteine adduct coupled to the cysteine at position 299 but that such an adduct does not form when an alanine is present (i.e., T299A).
[0057] FIG. 12 shows the decreased effector function of the aglycosylated antibody IgG1 variants of the invention as a function of FcγRI (upper panel) or FcγRIII (lower) binding. The T299C variant, which is both aglycosylated and modified by a cysteine adduct, has less effector function (FcγRI binding) as compared to merely aglycosylated antibodies (upper panel).
[0058] FIG. 13 shows the decreased effector function of the aglycosylated antibody IgG4 variant of the invention as a function of FcγRI (upper panel) or FcγRIII (lower) binding. The T299A IgG4 variant has less effector function (FcγRI binding) as compared to the aglycosylated IgG1 form.
[0059] FIG. 14 shows the decreased effector function of the aglycosyl IgG1 antibody (i.e., hu5c8) as a function of binding to the complement protein C1q. The T299C variant, which is both aglycosylated and modified by a cysteine adduct, has less effector function (i.e., C1q binding) as compared to the aglycosylated only form.
[0060] FIG. 15 shows the decreased effector function of the aglycosyl IgG4 antibody (i.e., hu5c8) as a function of binding to the complement protein C1q. The T299A IgG4 variant has less effector function (i.e., C1q binding) as compared to the aglycosylated IgG1 variant.
DETAILED DESCRIPTION OF THE INVENTION
[0061] In order to provide a clear understanding of the specification and claims, the following definitions are conveniently provided below.
DEFINITIONS
[0062] The term “antibody” includes monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), chimeric antibodies, CDR-grafted antibodies, humanized antibodies, human antibodies, and fragments thereof where reduced glycosylation and/or effector function is desirable, for example, an antibody light chain (VL), an antibody heavy chain (VH), a single chain antibody (scFv), a F(ab′)2 fragment, a Fab fragment, an Fd fragment, an Fv fragment, and a single domain antibody fragment (DAb).
[0063] The term “parent antibody” includes any antibody for which modification of the glycosylation, effector function, and/or the providing of a preferred or desirable side chain chemistry for adding, for example, a functional moiety, is desired. Thus, the parent antibody represents the original antibody on which the methods of the instant invention are performed. The parent polypeptide may comprise a native sequence (i.e. a naturally occurring) antibody (including a naturally occurring allelic variant), or an antibody with pre-existing amino acid sequence modifications (such as insertions, deletions and/or other alterations) of a naturally occurring sequence. The parent antibody may be a monoclonal, chimeric, CDR-grafted, humanized, or human antibody.
[0064] The terms “antibody variant” or “modified antibody”, includes an antibody which has an amino acid sequence or amino acid side chain chemistry which differs from that of the parent antibody by at least one amino acid or amino acid modification as described herein. In preferred embodiments, the antibody variant will have reduced glycosylation, and, optionally, reduced effector function as compared to the parent antibody and/or further comprise one or more functional moieties.
[0065] The term “first amino acid residue” refers to the amino acid residue (or position) of the polypeptide which is modified by the insertion, substitution, or deletion of an amino acid residue or by directly altering the side chain chemistry of the existing amino acid residue, such that the modified amino acid residue (or residue position) is different and thereby reduces or eliminates glycosylation of a second amino acid residue. Preferably, the modification of the first amino acid, while influencing the glycosylation and/or effector function of the polypeptide (and optionally providing a site for linking a functional moiety), the modification does not significantly alter other desired functions of the polypeptide nor does the functional moiety attached thereto. For example, where the Fc containing polypeptide is an antibody, the modification of the first amino acid does not significantly alter the antigen-binding activity of the antibody.
[0066] The term “second amino acid residue” refers to the amino acid residue of the polypeptide which is capable of being covalently linked to one or more carbohydrates, for example, glycosylated.
[0067] The term “preferred side chain chemistry” refers to a chemistry, for example, an amino acid residue side chain or R-group chemistry that imparts a desirable characteristic to the polypeptide. The preferred side chain chemistry is introduced at the first amino acid position by amino acid substitution, by chemical substitution such that its side chain chemistry is modified, or by an amino acid addition or deletion such that a different amino acid side chain chemistry is provided at the first amino acid position. As described herein, modification of the side chain chemistry of the parent antibody so that it contains the preferred side chain chemistry reduces glycosylation at a second amino acid position, resulting in reduced effector function. The modification also provides a site for linking a desirable functional moiety. In certain embodiments, a determination as to the preferred side chain chemistry may be informed by an in silico or computer-based approach for determining the steric bulk, and/or charge of the side chain chemistry to be introduced (e.g., by substitution) at the first amino acid position.
[0068] The term “amino acid” includes alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine (Cys or C); glutamine (Gln or Q); glutamic acid (Glu or E); glycine (Gly or G); histidine (His or H); isoleucine (Ile or I): leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Val or V). Non-traditional amino acids are also within the scope of the invention and include norleucine, ornithine, norvaline, homoserine, and other amino acid residue analogues such as those described in Ellman et al. Meth. Enzym. 202:301-336 (1991). To generate such non-naturally occurring amino acid residues, the procedures of Noren et al. Science 244:182 (1989) and Ellman et al., supra, can be used. Briefly, these procedures involve chemically activating a suppressor tRNA with a non-naturally occurring amino acid residue followed by in vitro transcription and translation of the RNA. Introduction of the non-traditional amino acid can also be achieved using peptide chemistries know in the art.
[0069] The term “preferred side chain chemistry is of sufficient steric bulk” includes the side chain chemistry of an amino acid residue having sufficient steric bulk so as to inhibit the glycosylation of an Fc containing polypeptide and/or its effector function. Such residues include, for example, phenylalanine, tyrosine, tryptophan, arginine, lysine, histidine, glutamic acid, glutamine, and methionine, or analogs or mimetics thereof.
[0070] The term “preferred side chain chemistry is of sufficient charge” or “electrostatic charge” includes the side chain chemistry of an amino acid residue having sufficient charge so as to inhibit the glycosylation of an Fc containing polypeptide and/or its effector function. Such residues include, for example, the negatively charged amino acid residues, e.g., aspartic acid, glutamic acid, or analogs or mimetics thereof, and the positively charged amino acid residues, e.g., lysine, arginine, histidine, and analogs or mimetics thereof.
[0071] The term “preferred side chain chemistry is of sufficient steric bulk and charge” includes the side chain chemistry of an amino acid residue having sufficient steric bulk and charge so as to inhibit the glycosylation of an Fc containing polypeptide and/or its effector function. Such residues include, for example, lysine, arginine, tyrosine, and analogs or mimetics thereof.
[0072] The term “sufficient” as used herein, generally refers to the preferred modifications described herein which achieve at least one of the following in an Fc containing polypeptide: reduced glycosylation of the polypeptide; reduced effector function of the polypeptide; and/or providing of a site for linking a functional moiety.
[0073] The term “functional moiety” includes moieties which, preferably, add a desirable function to the variant polypeptide. Preferably, the function is added without significantly altering an intrinsic desirable activity of the polypeptide, e.g., in the case of an antibody, the antigen-binding activity of the molecule. A variant polypeptide of the invention may comprise one or more functional moieties, which may be the same or different. Examples of useful functional moieties include, but are not limited to, a blocking moiety, a detectable moiety, a diagnostic moiety, and a therapeutic moiety. Exemplary blocking moieties include moieties of sufficient steric bulk and/or charge such that reduced glycosylation occurs, for example, by blocking the ability of a glycosidase to glycosylate the polypeptide. The blocking moiety may additionally or alternatively, reduce effector function, for example, by inhibiting the ability of the Fc region to bind a receptor or complement protein. Preferred blocking moieties include cysteine adducts, cystine, mixed disulfide adducts, and PEG moieties. Exemplary detectable moieties include fluorescent moieties, radioisotopic moieties, radiopaque moieties, and the like. Exemplary diagnostic moieties include moieties suitable for revealing the presence of an indicator of a disease or disorder. Exemplary therapeutic moieties include, for example, anti-inflammatory agents, anti-cancer agents, anti-neurodegenerative agents, and anti-infective agents. The functional moiety may also have one or more of the above-mentioned functions. Other useful functional moieties are known in the art and described, below.
[0074] The term “pegylation”, “polyethylene glycol”, or “PEG” includes a polyalkylene glycol compound or a derivative thereof, with or without coupling agents or derviatization with coupling or activating moieties (e.g., with thiol, triflate, tresylate, azirdine, oxirane, or preferably with a maleimide moiety, e.g., PEG-maleimide). Other appropriate polyalkylene glycol compounds include, but are not limited to, maleimido monomethoxy PEG, activated PEG polypropylene glycol, but also charged or neutral polymers of the following types: dextran, colominic acids, or other carbohydrate based polymers, polymers of amino acids, and biotin derivatives.
[0075] The term “spatially positioned” includes the relative position or distance between the modified first amino acid position and the second amino acid position within a polypeptide where it is desirable to alter or reduce the glycosylation at the second amino acid position by modifying the first amino acid position. Amino acid distances of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-20 or more amino acid positions, or any interval of the foregoing ranges are within the scope of the invention. Methods of determining that the desired spatial positioning of the first and second amino acids achieves the desired effect, for example, reduced glycosylation and/or effector function, are known in the art and are described herein (see, e.g., Examples 1 and 4).
[0076] The term “effector function” refers to the functional ability of the Fc or constant region of an antibody to bind proteins and/or cells of the immune system. Typical effector functions include the ability to bind complement protein (e.g., the complement protein C1q), and/or an Fc receptor (FcR) (e.g., FcγRI, FcγRII, FcγRIII, and/or FcγRIIIb). The functional consequences of being able to bind one or more of the foregoing include opsonization, phagocytosis, antigen-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or effector cell modulation. A decrease in effector function refers to a decrease in one or more of the biochemical or cellular activities, while maintaining the antigen binding activity of the variable region of the antibody (or fragment thereof). Decreases in effector function, e.g., Fc binding to an Fc receptor or complement protein, can be expressed in terms of fold reduction (e.g., reduced by 1-fold, 2-fold, and the like) and can be calculated based on, e.g., the percent reductions in binding activity determined using the assays described herein (see, e.g., Example 4) or assays known in the art.
[0077] The term “glycosylation” refers to the covalent linking of one or more carbohydrates to a polypeptide. Typically, glycosylation is a posttranslational event which can occur within the intracellular milieu of a cell or extract therefrom. The term glycosylation includes, for example, N-linked glycosylation (where one or more sugars are linked to an asparagine residue) and/or O-linked glycosylation (where one or more sugars are linked to an amino acid residue having a hydroxyl group (e.g., serine or threonine).
[0078] All amino acid numberings herein for an Fc region of a polypeptide correspond to the Kabat numbering system as described, e.g., by Kabat et al., in “Sequences of Proteins of Immunological Interest”, U.S. Dept. Health and Human Services, 1983 and 1987.
DETAILED DESCRIPTION
[0079] A method has been developed to produce aglycosylated antigen-binding polypeptides, for example, antibodies or Fc-containing fusion proteins, by altering a first amino acid residue that inhibits the glycosylation at a second amino acid residue. The method is especially well suited for producing therapeutic aglycosylated Fc-containing polypeptides in eukaryotic cells with only minimal amino acid alterations to the polypeptide. The methods of the present invention thereby avoids introducing into the polypeptide amino acid sequence that can be immunogenic.
[0080] Preferably, the modification of the first amino acid, while influencing the glycosylation and/or effector function of the polypeptide (and optionally providing a site for linking a functional moiety), does not significantly alter other desired functions of the polypeptide nor does the functional moiety attached thereto. For example, where the Fc containing polypeptide is an antibody, the modification of the first amino acid does not significantly alter the antigen-binding activity of the antibody.
[0081] Accordingly, the method is suitable for producing therapeutic antibodies, for example, IgG antibodies, where altered or reduced effector function is desired. The altered or reduced effector function is achieved by reducing or eliminating the glycosylation of the Fc region of the antibody using the method of the invention (FIG. 1 ). In particular, a first amino acid residue(s) is targeted for alteration (e.g., by substitution, insertion, deletion, or by chemical modification) which inhibits the glycosylation of a second amino acid residue. The resultant antibody is aglycosylated at the second amino acid residue and has altered or reduced effector function, e.g., complement binding activity or effector cell activity such as binding to an Fc receptor.
[0082] In certain embodiments, the reduced effector function is reduced binding to an Fc receptor (FcR), such as the FcγRI, FcγRII, FcγRIII, and/or FcγRIIIb receptor or a complement protein, for example, the complement protein C1q. This change in binding can be by a factor of about 1 fold or more, e.g., by about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 50, or 100-fold or more, or by any interval or range thereof.
[0083] These decreases in effector function, e.g., Fc binding to an Fc receptor or complement protein, are readily calculated based on, e.g., the percent reductions in binding activity determined using the assays described herein (see, e.g., Example 4) or assays known in the art.
[0084] In another embodiment, the first amino acid residue is modified or substituted to contain a preferred side chain chemistry of sufficient steric bulk and/or charge such that reduced glycosylation and or effector function is achieved.
[0085] Exemplary amino acid residues having side chain chemistry of sufficient steric bulk include phenylalanine, tyrosine, tryptophan, arginine, lysine, histidine, glutamic acid, glutamine, and methionine, or analogs or mimetics thereof.
[0086] Exemplary amino acid residues having side chain chemistry of sufficient charge include, for example, negatively charged amino residues, e.g., aspartic acid, glutamic acid analogs or mimetics thereof, and positively charged amino acid residues, e.g., lysine, arginine, histidine, and analogs or mimetics thereof.
[0087] Further, amino acid residues that are uncharged at physiological pH may become charged when residing in an environment that alters the physiological pH, e.g., serine, threonine, cysteine, methionine, asparagine, glutamine, tyrosine, and analogs or mimetics thereof. For example, uncharged amino acid residues can be buried inside a folded protein and experience a shift in pKa, thereby altering the charge of the residue compared to the charge at physiological pH.
[0088] In one embodiment, the preferred amino acid residue is of sufficient steric bulk and charge such that the residue inhibits glycosylation at a second amino acid position. Such amino acids include, for example, lysine, arginine, and tyrosine.
[0089] In preferred embodiments of the present invention, the amino acid residue that is modified can be selected for additional properties, e.g., to serve as a site for coupling desirable functional moieties which impart desirable properties to the polypeptide. Examples of such preferred moieties include, e.g., blocking moieties, detectable moieties, diagnostic moieties, and therapeutic moieties.
[0090] In another embodiment, the variant polypeptide of a parent polypeptide contains an Fc region, which comprises a modified first amino acid residue, wherein the modified first amino acid is spatially positioned such that reduced glycosylation at a second amino acid is achieved, whereby the variant polypeptide has reduced effector function as compared to the parent polypeptide.
[0091] Preferred spatial positioning can be based on the predicted proximity of the first amino acid to the second amino acid as well as the steric bulk and/or charge of the preferred side chain chemistry to be introduced at the first amino acid position. Alternatively, a determination as to the optimal spatial positioning may be informed by empirical observations after substitutions of a preferred amino acid side chain chemistry at one or more positions and/or using an art recognized in silico or computer-based approach for determining the steric bulk, charge, and/or the distance of the first amino acid position from the second amino acid position. Amino acid distances of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-20 or more residue positions, or any interval of the foregoing ranges, are within the scope of the invention. Thus, in certain preferred embodiments, the modified first amino acid is spatially positioned from the second amino acid by an interval of at least 1 amino acid position or more, for example, by 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid positions or more.
[0092] Methods of determining that the desired spatial positioning of the first and second amino acids achieves the desired effect, for example, reduced glycosylation and/or effector function, are described herein (see, e.g., Examples 1 and 4).
[0093] In a preferred embodiment, the polypeptide of the invention is an Fc containing polypeptide such as an antibody, and preferably IgG immunoglobulin, e.g., of the subtype IgG1, IgG2, IgG3, or IgG4, and preferably, of the subtype IgG1 or IgG4. In a preferred embodiment, the forgoing polypeptide binds to an antigen such as a ligand, cytokine, receptor, cell surface antigen, or cancer cell antigen.
[0094] Because the invention provides an isolated nucleic acid encoding any one of the foregoing polypeptides, the nucleic acid can be introduced into a vector and expressed in a host cell. Accordingly, a polypeptide of the invention can be produced by culturing a suitable host cell containing a nucleic acid encoding a polypeptide of the invention under appropriate culture conditions for producing the polypeptide.
[0095] In a preferred embodiment, the polypeptide of the invention has a first amino acid that has been modified to have a cysteine residue or side chain chemistry thereof, i.e., a thiol, such that the polypeptide, under the above culture conditions, is capable of forming an adduct with a free cysteine provided under the culture conditions. In a preferred embodiment, the resulting polypeptide has reduced glycosylation and effector function.
[0096] In a related embodiment, the polypeptide can be further manipulated, for example, subjected to reducing conditions, such that the cysteine adduct, cystine, mixed disulfide adduct, or disulfide linkage, is removed thereby providing a site for further modifying the polypeptide with a functional moiety, for example, a pegylation moiety.
[0097] In another embodiment, the polypeptide has a first amino acid residue and second amino acid residue that are near or within a glycosylation motif, for example, an N-linked glycosylation motif that contains the amino acid sequence NXT or NXS. In a particular embodiment, the polypeptide of the method has a first amino acid residue modified by an amino acid substitution. In a related embodiment, the first amino acid residue is amino acid 299 and the second amino acid residue is amino acid 297, according to the Kabat numbering.
[0098] In another embodiment, the amino acid substitution is selected from the group consisting of T299A, T299N, T299G, T299Y, T299C, T299H, T299E, T299D, T299K, T299R, T299G, T2991, T299L, T299M, T299F, T299P, T299W, and T299V according to the Kabat numbering.
[0099] In a particular embodiment, the amino acid substitution is T299C or T299A.
[0100] Although the method of the invention described herein uses an IgG antibody that is normally N-glycosylated at a particular residue in the Fc region (amino acid 297) (FIGS. 1-2 ), it is understood that the method can be equally applied to an Fc region within any polypeptide. When the polypeptide is an antibody, the antibody can be synthetic, naturally-derived (e.g., from serum), produced by a cell line (e.g., a hybridoma), or produced in a transgenic organism. Still further, the method may also be applied to a polypeptide which does not comprise an Fc region provided the polypeptide comprises at least one glycosylation site.
[0101] The method offers several advantages over current mutagenesis methods, for example, because the method can be used to inhibit glycosylation of the polypeptide in a way that is minimally disruptive (FIG. 2 , left panel), e.g., without the mutation of the normally glycosylated residue, deletion of the glycosylation site, or enzymatic removal of the sugar moieties. Accordingly, the structure of the polypeptide is maintained, the binding affinity of the polypeptide for antigen is maintained, immunogenicity of the polypeptide is avoided, and the polypeptide can be, if desired, coupled to a desirable functional moiety (FIG. 2 , right panel). Such functional moieties can further abrogate effector function or improve the half-life of the polypeptide or achieve desirable therapeutic function. Moreover, the methods of the invention can be performed using standard genetic engineering techniques.
1. Identifying Glycosylation Sites
[0102] The method is performed by identifying a glycosylation site in an Fc-containing polypeptide, for example, an antibody, in one embodiment, an IgG antibody. The identification of the glycosylation site can be experimental or based on sequence analysis or modeling data. Consensus motifs, that is, the amino acid sequence recognized by various glycosyl transferases, have been described. For example, the consensus motif for an N-linked glycosylation motif is frequently NXT or NXS, where X can be any amino acid except proline (FIG. 2 ). Several algorithms for locating a potential glycosylation motif have also been described. Accordingly, to identify potential glycosylation sites within an antibody or Fc-containing fragment, the sequence of the antibody is examined, for example, by using publicly available databases such as the website provided by the Center for Biological Sequence Analysis (see the NetNGlyc 1.0 Server for predicting N-linked glycosylation sites) and the NetOGlyc 3.1 Server for predicting O-linked glycosylation sites). Additional methods for altering glycosylation sites of antibodies are described, e.g., in U.S. Pat. Nos. 6,350,861 and 5,714,350.
[0103] In certain cases, the glycosylation of a given motif will depend on other features of the protein, the type of cell or cell extract and the conditions under which the antibody is produced or contacted with such a cell or extract. To the extent that a given cell or extract has resulted in the glycosylation of a given motif, art recognized techniques for determining if the motif has been glycosylated are available, for example, using gel electrophoresis and/or mass spectroscopy, as described herein.
[0104] Identification of an actual or potential glycosylation motif also reveals the residue to which the sugars are covalently linked. For example, N-linked glycosylation results in the linking of a sugar residue (glycan) to the terminal side-chain nitrogen at an asparagine residue. In another example, O-linked glycosylation results in the covalent linking of a sugar residue (glycan) to an amino acid reside having a hydroxyl side group such as serine or threonine. In either case, the method of the invention does not alter the residue to which one or more sugars would be covalently linked. Rather, the method of the invention employs the alteration of a residue different from the residue which would be normally covalently linked to a sugar residue by a mechanism that operates in cis thereby inhibiting the coupling of one or more sugars to the residue but without requiring the alteration of the actual residue capable of being linked to a sugar, i.e., glycosylated.
[0105] The methods of the invention are applicable to a variety of uses including, the bioproduction of aglycosylated polypeptides using eukaryotic cells. Such aglycosylated polypeptides, for example, antibodies, are desirable therapeutics for the treatment of human disease.
2. Production of Antibodies with Altered Fc Regions
[0106] Having selected the antibody to be improved, for example, a chimeric, human, humanized, or synthetic antibody, a variety of methods are available for producing such antibodies. Because of the degeneracy of the code, a variety of nucleic acid sequences will encode each antibody amino acid sequence. The desired nucleic acid sequences can be produced by de novo solid-phase DNA synthesis or by PCR mutagenesis of an earlier prepared polynucleotide encoding the antibody. Oligonucleotide-mediated mutagenesis is one method for preparing a substitution, deletion, or insertion of an alteration (e.g., altered codon) that reduces the glycosylation of a second, usually proximal, amino acid. For example, the target polypeptide DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a single-stranded DNA template. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that incorporates the oligonucleotide primer, and encodes the selected alteration in the variant polypeptide-DNA. In one embodiment, genetic engineering, e.g., primer-based PCR mutagenesis, is sufficient to alter the first amino acid, as defined herein, for producing a polynucleotide encoding a polypeptide that, when expressed in a eukaryotic cell, will now have an aglycosylated region, for example, aglycosylated Fc region. The antibodies produced as described above typically comprise at least a portion of an antibody constant region (Fc), typically that of a human immunoglobulin. Ordinarily, the antibody will contain both light chain and heavy chain constant regions. The heavy chain constant region usually includes CH1, hinge, CH2, and CH3 regions. It is understood, however, that the antibodies described herein include antibodies having all types of constant regions, including IgM, IgG, IgD, and IgE, and any isotype, including IgG1, IgG2, IgG3, and IgG4. In one embodiment, the human isotype IgG1 is used. In another embodiment, the human isotype IgG4 is used. Light chain constant regions can be lambda or kappa. The humanized antibody may comprise sequences from more than one class or isotype. Antibodies can be expressed as tetramers containing two light and two heavy chains, as separate heavy chains, light chains, as Fab, Fab′ F(ab′)2, and Fv, or as single chain antibodies (sFv) in which heavy and light chain variable domains are linked through a spacer.
[0107] Methods for determining the effector function of a polypeptide comprising an Fc region, for example, an antibody, are described herein and include cell-based bridging assays to determine changes in the ability of a modified Fc region to bind to an Fc receptor. Other binding assays may be used to determine the ability of an Fc region to bind to a complement protein, for example, the C1q complement protein. Additional techniques for determining the effector function of a modified Fc region are described in the art.
3. Functional Moieties and the Chemistry of Linking Such Moieties to Fc-Containing Polypeptides
[0108] The invention provides antibodies and Fc-containing polypeptides that may be further modified to provide a desired effect. For example, in preferred embodiments, the first amino acid is modified to be a residue that not only alters the glycosylation of the polypeptide at a second site, but also provides a desired side chain chemistry.
[0109] In certain preferred embodiments, the side chain chemistry of the amino acid residue is capable of being linked, for example, covalently linked, to an additional moiety, i.e., a functional moiety such as, for example, a blocking moiety, a detectable moiety, a diagnostic moiety, and/or a therapeutic moiety. Exemplary functional moieties are first described below followed by useful chemistries for linking such functional moieties to the different amino acid side chain chemistries.
3.1 Functional Moieties
[0110] Examples of useful functional moieties include, but are not limited to, a blocking moiety, a detectable moiety, a diagnostic moiety, and a therapeutic moiety.
[0111] Exemplary blocking moieties include moieties of sufficient steric bulk and/or charge such that reduced glycosylation occurs, for example, by blocking the ability of a glycosidase to glycosylate the polypeptide. The blocking moiety may additionally or alternatively, reduce effector function, for example, by inhibiting the ability of the Fc region to bind a receptor or complement protein. Preferred blocking moieties include cysteine adducts and PEG moieties.
[0112] In a preferred embodiment, the blocking moiety is a cysteine, preferably a cysteine that has associated with a free cysteine, e.g., during or subsequent to the translation of the Fc containing polypeptide, e.g., in cell culture. Other blocking cysteine adducts include cystine, mixed disulfide adducts, or disulfide linkages.
[0113] In another preferred embodiment, the blocking moiety is a polyalkylene glycol moiety, for example, a PEG moiety and preferably a PEG-maleimide moiety. Preferred pegylation moieties (or related polymers) can be, for example, polyethylene glycol (“PEG”), polypropylene glycol (“PPG”), polyoxyethylated glycerol (“POG”) and other polyoxyethylated polyols, polyvinyl alcohol (“PVA) and other polyalkylene oxides, polyoxyethylated sorbitol, or polyoxyethylated glucose. The polymer can be a homopolymer, a random or block copolymer, a terpolymer based on the monomers listed above, straight chain or branched, substituted or unsubstituted as long as it has at least one active sulfone moiety. The polymeric portion can be of any length or molecular weight but these characteristics can affect the biological properties. Polymer average molecular weights particularly useful for decreasing clearance rates in pharmaceutical applications are in the range of 2,000 to 35,000 daltons. In addition, if two groups are linked to the polymer, one at each end, the length of the polymer can impact upon the effective distance, and other spatial relationships, between the two groups. Thus, one skilled in the art can vary the length of the polymer to optimize or confer the desired biological activity. PEG is useful in biological applications for several reasons. PEG typically is clear, colorless, odorless, soluble in water, stable to heat, inert to many chemical agents, does not hydrolyze, and is nontoxic. Pegylation can improve pharmacokinetic performance of a molecule by increasing the molecule's apparent molecular weight. The increased apparent molecular weight reduces the rate of clearance from the body following subcutaneous or systemic administration. In many cases, pegylation can decrease antigenicity and immunogenicity. In addition, pegylation can increase the solubility of a biologically-active molecule.
[0114] Pegylated antibodies and antibody fragments may generally be used to treat conditions that may be alleviated or modulated by administration of the antibodies and antibody fragments described herein. Generally the pegylated aglycosylated antibodies and antibody fragments have increased half-life, as compared to the nonpegylated aglycosylated antibodies and antibody fragments. The pegylated aglycosylated antibodies and antibody fragments may be employed alone, together, or in combination with other pharmaceutical compositions.
[0115] Examples of detectable moieties which are useful in the methods and polypeptides of the invention include fluorescent moieties, radioisotopic moieties, radiopaque moieties, and the like, e.g. detectable labels such as biotin, fluorophores, chromophores, spin resonance probes, or radiolabels. Exemplary fluorophores include fluorescent dyes (e.g. fluorescein, rhodamine, and the like) and other luminescent molecules (e.g. luminal). A fluorophore may be environmentally-sensitive such that its fluorescence changes if it is located close to one or more residues in the modified protein that undergo structural changes upon binding a substrate (e.g. dansyl probes). Exemplary radiolabels include small molecules containing atoms with one or more low sensitivity nuclei (13C, 15N, 2H, 125I, 123I, 99Tc, 43K, 52Fe, 67Ga, 68Ga, 111In and the like). Other useful moieties are known in the art.
[0116] Examples of diagnostic moieties which are useful in the methods and polypeptides of the invention include detectable moieties suitable for revealing the presence of a disease or disorder. Typically a diagnostic moiety allows for determining the presence, absence, or level of a molecule, for example, a target peptide, protein, or proteins, that is associated with a disease or disorder. Such diagnostics are also suitable for prognosing and/or diagnosing a disease or disorder and its progression.
[0117] Examples of therapeutic moieties which are useful in the methods and polypeptides of the invention include, for example, anti-inflammatory agents, anti-cancer agents, anti-neurodegenerative agents, and anti-infective agents. The functional moiety may also have one or more of the above-mentioned functions.
[0118] Exemplary therapeutics include radionuclides with high-energy ionizing radiation that are capable of causing multiple strand breaks in nuclear DNA, and therefore suitable for inducing cell death (e.g., of a cancer). Exemplary high-energy radionuclides include: 90Y, 125I, 131I, 123I, 111In, 105Rh, 153Sm, 67Cu, 67Ga, 166Ho, 177Lu, 186Re and 188Re. These isotopes typically produce high energy α- or β-particles which have a short path length. Such radionuclides kill cells to which they are in close proximity, for example neoplastic cells to which the conjugate has attached or has entered. They have little or no effect on non-localized cells and are essentially non-immunogenic.
[0119] Exemplary therapeutics also include cytotoxic agents such as cytostatics (e.g. alkylating agents, DNA synthesis inhibitors, DNA-intercalators or cross-linkers, or DNA-RNA transcription regulators), enzyme inhibitors, gene regulators, cytotoxic nucleosides, tubulin binding agents, hormones and hormone antagonists, anti-angiogenesis agents, and the like.
[0120] Exemplary therapeutics also include alkylating agents such as the anthracycline family of drugs (e.g. adriamycin, carminomycin, cyclosporin-A, chloroquine, methopterin, mithramycin, porfiromycin, streptonigrin, porfiromycin, anthracenediones, and aziridines). In another embodiment, the chemotherapeutic moiety is a cytostatic agent such as a DNA synthesis inhibitor. Examples of DNA synthesis inhibitors include, but are not limited to, methotrexate and dichloromethotrexate, 3-amino-1,2,4-benzotriazine 1,4-dioxide, aminopterin, cytosine β-D-arabinofuranoside, 5-fluoro-5′-deoxyuridine, 5-fluorouracil, ganciclovir, hydroxyurea, actinomycin-D, and mitomycin C. Exemplary DNA-intercalators or cross-linkers include, but are not limited to, bleomycin, carboplatin, carmustine, chlorambucil, cyclophosphamide, cis-diammineplatinum(II) dichloride (cisplatin), melphalan, mitoxantrone, and oxaliplatin.
[0121] Exemplary therapeutics also include transcription regulators such as actinomycin D, daunorubicin, doxorubicin, homoharringtonine, and idarubicin. Other exemplary cytostatic agents that are compatible with the present invention include ansamycin benzoquinones, quinonoid derivatives (e.g. quinolones, genistein, bactacyclin), busulfan, ifosfamide, mechlorethamine, triaziquone, diaziquone, carbazilquinone, indoloquinone EO9, diaziridinyl-benzoquinone methyl DZQ, triethylenephosphoramide, and nitrosourea compounds (e.g. carmustine, lomustine, semustine).
[0122] Exemplary therapeutics also include cytotoxic nucleosides such as, for example, adenosine arabinoside, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, ftorafur, and 6-mercaptopurine; tubulin binding agents such as taxoids (e.g. paclitaxel, docetaxel, taxane), nocodazole, rhizoxin, dolastatins (e.g. Dolastatin-10, -11, or -15), colchicine and colchicinoids (e.g. ZD6126), combretastatins (e.g. Combretastatin A-4, AVE-6032), and vinca alkaloids (e.g. vinblastine, vincristine, vindesine, and vinorelbine (navelbine)); anti-angiogenesis compounds such as Angiostatin K1-3, DL-α-difluoromethyl-ornithine, endostatin, fumagillin, genistein, minocycline, staurosporine, and (±)-thalidomide.
[0123] Exemplary therapeutics also include hormones and hormone antagonists, such as corticosteroids (e.g. prednisone), progestins (e.g. hydroxyprogesterone or medroprogesterone), estrogens, (e.g. diethylstilbestrol), antiestrogens (e.g. tamoxifen), androgens (e.g. testosterone), aromatase inhibitors (e.g. aminogluthetimide), 17-(allylamino)-17-demethoxygeldanamycin, 4-amino-1,8-naphthalimide, apigenin, brefeldin A, cimetidine, dichloromethylene-diphosphonic acid, leuprolide (leuprorelin), luteinizing hormone-releasing hormone, pifithrin-α, rapamycin, sex hormone-binding globulin, and thapsigargin.
[0124] Exemplary therapeutics also include enzyme inhibitors such as, S(+)-camptothecin, curcumin, (−)-deguelin, 5,6-dichlorobenz-imidazole 1-β-D-ribofuranoside, etoposide, formestane, fostriecin, hispidin, 2-imino-1-imidazolidineacetic acid (cyclocreatine), mevinolin, trichostatin A, tyrphostin AG 34, and tyrphostin AG 879.
[0125] Exemplary therapeutics also include gene regulators such as 5-aza-2′-deoxycytidine, 5-azacytidine, cholecalciferol (vitamin D3), 4-hydroxytamoxifen, melatonin, mifepristone, raloxifene, trans-retinal (vitamin A aldehydes), retinoic acid, vitamin A acid, 9-cis-retinoic acid, 13-cis-retinoic acid, retinol (vitamin A), tamoxifen, and troglitazone.
[0126] Exemplary therapeutics also include cytotoxic agents such as, for example, the pteridine family of drugs, diynenes, and the podophyllotoxins. Particularly useful members of those classes include, for example, methopterin, podophyllotoxin, or podophyllotoxin derivatives such as etoposide or etoposide phosphate, leurosidine, vindesine, leurosine and the like.
[0127] Still other cytotoxins that are compatible with the teachings herein include auristatins (e.g. auristatin E and monomethylauristan E), calicheamicin, gramicidin D, maytansanoids (e.g. maytansine), neocarzinostatin, topotecan, taxanes, cytochalasin B, ethidium bromide, emetine, tenoposide, colchicin, dihydroxy anthracindione, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs thereof.
[0128] Other types of functional moieties are known in the art and can be readily used in the methods and compositions of the present invention based on the teachings contained herein.
3.2. Chemistries for Linking Functional Moieties to Amino Acid Side Chains
[0129] Chemistries for linking the foregoing functional moieties be they small molecules, nucleic acids, polymers, peptides, proteins, chemotherapeutics, or other types of molecules to particular amino acid side chains are known in the art (for a detailed review of specific linkers see, for example, Hermanson, G. T., Bioconjugate Techniques, Academic Press (1996)).
[0130] Exemplary art recognized linking groups for sulfhydryl moieties (e.g., cysteine, or thiol side chain chemistries) include, but are not limited to, activated acyl groups (e.g., alpha-haloacetates, chloroacetic acid, or chloroacetamide), activated alkyl groups, Michael acceptors such as maleimide or acrylic groups, groups which react with sulfhydryl moieties via redox reactions, and activated di-sulfide groups. The sulfhydryl moieties may also be linked by reaction with bromotrifluoroacetone, alpha-bromo-beta-(5-imidazoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl-2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.
[0131] In a preferred embodiment, the cysteine or thiol side chain chemistry is linked during or subsequent to the production of an Fc containing polypeptide. For example, when producing the modified Fc containing polypeptide using cell culture, conditions are provided such that a free cysteine in solution can form a cysteine adduct with the thiol side chain of the Fc containing polypeptide. The so formed adduct may be used to inhibit glycosylation and/or effector function, or, subsequently subjected to reducing conditions to remove the adduct and thereby allow for the use of one of the aforementioned sulfhydryl chemistries.
[0132] Exemplary art recognized linking groups for hydroxyl moieties (e.g., serine, threonine, or tyrosine side chain chemistries) include those described above for sulfhydryl moieties including activated acyl groups, activated alkyl groups, and Michael acceptors.
[0133] Exemplary art recognized linking groups for amine moieties (e.g., asparagine or arginine side chain chemistries) include, but are not limited to, N-succinimidyl, N-sulfosuccinimidyl, N-phthalimidyl, N-sulfophthalimidyl, 2-nitrophenyl, 4-nitrophenyl, 2,4-dinitrophenyl, 3-sulfonyl-4-nitrophenyl, 3-carboxy-4-nitrophenyl, imidoesters (e.g., methyl picolinimidate), pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methyliosurea, and 2,4-pentanedione.
[0134] Exemplary art recognized linking groups for acidic moieties (e.g., aspartic acid or glutamic side chain chemistries) include activated esters and activated carbonyls. Acidic moieties can also be selectively modified by reaction with carbodiimides (R′N—C—N—R′) such as 1-cyclohexyl-3-[2-morpholinyl-(4-ethyl)]carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide.
[0135] Where the functional moiety desired is a pegylation moiety, pegylation reactions known in the art are employed or as described herein (see also, e.g., Example 3). For example, in one method, the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer). A water-soluble polymer for pegylation of the antibodies and antibody fragments of the invention is polyethylene glycol (PEG). In another embodiment, the polymer for pegylation is polyethylene glycol-maleimide (i.e., PEG-maleimide).
[0136] Methods for preparing pegylated antibodies and antibody fragments of the invention will generally comprise the steps of a) reacting the antibody or antibody fragment with polyethylene glycol, such as a reactive ester or aldehyde derivative of PEG, under conditions whereby the antibody or antibody fragment becomes attached to one or more PEG groups, and b) obtaining the reaction products. It will be apparent to one of ordinary skill in the art to select the optimal reaction conditions or the acylation reactions based on known parameters and the desired result. In one embodiment, a particular amino acid reside can be targeted, for example, the first amino acid residue altered in order to inhibit glycosylation of a second amino acid residue, and preferably where the first amino acid is a cysteine or has a thiol chemistry.
4. Expression of Recombinant Antibodies
[0137] The modified antibodies of the invention are typically produced by recombinant expression. Nucleic acids encoding light and heavy chain variable regions, optionally linked to constant regions, are inserted into expression vectors. The light and heavy chains can be cloned in the same or different expression vectors. The DNA segments encoding immunoglobulin chains are operably linked to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides. Expression control sequences include, but are not limited to, promoters (e.g., naturally-associated or heterologous promoters), signal sequences, enhancer elements, and transcription termination sequences. Preferably, the expression control sequences are eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and the collection and purification of the crossreacting antibodies.
[0138] These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors contain selection markers (e.g., ampicillin-resistance, hygromycin-resistance, tetracycline resistance or neomycin resistance) to permit detection of those cells transformed with the desired DNA sequences (see, e.g., Itakura et al., U.S. Pat. No. 4,704,362).
[0139] E. coli is one prokaryotic host particularly useful for cloning the polynucleotides (e.g., DNA sequences) of the present invention. Other microbial hosts suitable for use include bacilli, such as Bacillus subtilus, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species.
[0140] Other microbes, such as yeast, are also useful for expression. Saccharomyces and Pichia are exemplary yeast hosts, with suitable vectors having expression control sequences (e.g., promoters), an origin of replication, termination sequences and the like as desired. Typical promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes responsible for methanol, maltose, and galactose utilization.
[0141] In addition to microorganisms, mammalian tissue culture may also be used to express and produce the polypeptides of the present invention (e.g., polynucleotides encoding immunoglobulins or fragments thereof). See Winnacker, From Genes to Clones, VCH Publishers, N.Y., N.Y. (1987). Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting heterologous proteins (e.g., intact immunoglobulins) have been developed in the art, and include CHO cell lines, various COS cell lines, HeLa cells, 293 cells, myeloma cell lines, transformed B-cells, and hybridomas. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, and an enhancer (Queen et al., Immunol. Rev. 89:49 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, adenovirus, bovine papilloma virus, cytomegalovirus and the like. See Co et al., J. Immunol. 148:1149 (1992).
[0142] Alternatively, antibody-coding sequences can be incorporated in transgenes for introduction into the genome of a transgenic animal and subsequent expression in the milk of the transgenic animal (see, e.g., Deboer et al., U.S. Pat. No. 5,741,957, Rosen, U.S. Pat. No. 5,304,489, and Meade et al., U.S. Pat. No. 5,849,992). Suitable transgenes include coding sequences for light and/or heavy chains in operable linkage with a promoter and enhancer from a mammary gland specific gene, such as casein or beta lactoglobulin.
[0143] The vectors containing the polynucleotide sequences of interest (e.g., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment, electroporation, lipofection, biolistics or viral-based transfection may be used for other cellular hosts. (See generally Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Press, 2nd ed., 1989). Other methods used to transform mammalian cells include the use of polybrene, protoplast fusion, liposomes, electroporation, and microinjection (see generally, Sambrook et al., supra). For production of transgenic animals, transgenes can be microinjected into fertilized oocytes, or can be incorporated into the genome of embryonic stem cells, and the nuclei of such cells transferred into enucleated oocytes.
[0144] The antibodies of the invention can be expressed using a single vector or two vectors. When the antibody heavy and light chains are cloned on separate expression vectors, the vectors are co-transfected to obtain expression and assembly of intact immunoglobulins. Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present invention can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, HPLC purification, gel electrophoresis and the like (see generally Scopes, Protein Purification (Springer-Verlag, N.Y., (1982)). Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses.
5. Prophylactic, Diagnostic, and Therapeutic Methods
[0145] The present invention is also directed inter alia to the production of aglycosylated antibodies suitable for the prognosis, diagnosis, or treatment of diseases associated with immune disorders, including for example, disorders where it is desirable to bind an antigen using a therapeutic antibody but refrain from triggering effector function.
[0146] Accordingly, in certain embodiments, the aglycosylated antibodies or antigen-binding fragments of the present invention are useful in the prevention or treatment of immune disorders including, for example, glomerulonephritis, scleroderma, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel diseases or rheumatoid arthritis. In another embodiment, the antibodies or antigen-binding fragments of the invention can be used to treat or prevent inflammatory disorders, including, but not limited to, Alzheimer's, severe asthma, atopic dermatitis, cachexia, CHF-ischemia, coronary restinosis, Crohn's disease, diabetic nephropathy, lymphoma, psoriasis, fibrosis/radiation-induced, juvenile arthritis, stroke, inflammation of the brain or central nervous system caused by trauma, and ulcerative colitis.
[0147] Other inflammatory disorders which can be prevented or treated with the aglycosylated antibodies or antigen-binding fragments of the invention include inflammation due to corneal transplantation, chronic obstructive pulmonary disease, hepatitis C, multiple myeloma, and osteoarthritis.
[0148] In another embodiment, the antibodies or Fc-containing fragments of the invention can be used to prevent or treat neoplasia, including, but not limited to bladder cancer, breast cancer, head and neck cancer, Kaposi's sarcoma, melanoma, ovarian cancer, small cell lung cancer, stomach cancer, leukemia/lymphoma, and multiple myeloma. Additional neoplasia conditions include, cervical cancer, colo-rectal cancer, endometrial cancer, kidney cancer, non-squamous cell lung cancer, and prostate cancer.
[0149] In another embodiment, the antibodies or antigen-binding fragments of the invention can be used to prevent or treat neurodegenerative disorders, including, but not limited to Alzheimer's, stroke, and traumatic brain or central nervous system injuries. Additional neurodegenerative disorders include ALS/motor neuron disease, diabetic peripheral neuropathy, diabetic retinopathy, Huntington's disease, macular degeneration, and Parkinson's disease.
[0150] In still another embodiment, the antibody or Fc-containing fragment of the invention an be used to prevent or treat an infection caused by a pathogen, for example, a virus, prokaryotic organism, or eukaryotic organism.
[0151] In clinical applications, a subject is identified as having or at risk of developing one of the above-mentioned conditions by exhibiting at least one sign or symptom of the disease or disorder. At least one antibody or antigen-binding fragment thereof of the invention or compositions comprising at least one antibody or antigen-binding fragment thereof of the invention is administered in a sufficient amount to treat at least one symptom of a disease or disorder, for example, as mentioned above. In one embodiment, a subject is identified as exhibiting at least one sign or symptom of a disease or disorder associated with detrimental CD154 activity (also known as CD40 ligand or CD40L; see, e.g., Yamada et al., Transplantation, 73:S36-9 (2002); Schonbeck et al., Cell. Mol. Life Sci. 58:4-43 (2001); Kirk et al., Philos. Trans. R. Soc. Lond. B. Sci. 356:691-702 (2001); Fiumara et al., Br. J. Haematol. 113:265-74 (2001); and Biancone et al., Int. J. Mol. Med. 3(4):343-53 (1999)).
[0152] Accordingly, an aglycosylated antibody of the invention is suitable for administration as a therapeutic immunological reagent to a subject under conditions that generate a beneficial therapeutic response in a subject, for example, for the prevention or treatment of a disease or disorder, as for example, described herein.
[0153] Therapeutic agents of the invention are typically substantially pure from undesired contaminant. This means that an agent is typically at least about 50% w/w (weight/weight) purity, as well as being substantially free from interfering proteins and contaminants. Sometimes the agents are at least about 80% w/w and, more preferably at least 90 or about 95% w/w purity. However, using conventional protein purification techniques, for example as described herein, homogeneous peptides of at least 99% W/w can be obtained.
[0154] The methods can be used on both asymptomatic subjects and those currently showing symptoms of disease. The antibodies used in such methods can be human, humanized, chimeric or nonhuman antibodies, or fragments thereof (e.g., antigen binding fragments) and can be monoclonal or polyclonal.
[0155] In another aspect, the invention features administering an antibody with a pharmaceutical carrier as a pharmaceutical composition. Alternatively, the antibody can be administered to a subject by administering a polynucleotide encoding at least one antibody chain. The polynucleotide is expressed to produce the antibody chain in the subject. Optionally, the polynucleotide encodes heavy and light chains of the antibody. The polynucleotide is expressed to produce the heavy and light chains in the subject. In exemplary embodiments, the subject is monitored for the level of administered antibody in the blood of the subject.
[0156] The invention thus fulfills a longstanding need for therapeutic regimes for preventing or ameliorating immune conditions, for example, CD154-associated immune conditions.
[0157] It is also understood the antibodies of the invention are suitable for diagnostic or research applications, especially, for example, an diagnostic or research application comprising a cell-based assay where reduced effector function is desirable.
6. Animal Models for Testing the Efficacy of Aglycosylated Antibodies
[0158] An antibody of the invention can be administered to a non-human mammal in need of, for example, an aglycosylated antibody therapy, either for veterinary purposes or as an animal model of human disease, e.g., an immune disease or condition stated above. Regarding the latter, such animal models may be useful for evaluating the therapeutic efficacy of antibodies of the invention (e.g., testing of effector function, dosages, and time courses of administration).
[0159] Examples of animal models which can be used for evaluating the therapeutic efficacy of antibodies or antigen-binding fragments of the invention for preventing or treating rheumatoid arthritis (RA) include adjuvant-induced RA, collagen-induced RA, and collagen mAb-induced RA (Holmdahl et al., (2001) Immunol. Rev. 184:184; Holmdahl et al., (2002) Ageing Res. Rev. 1:135; Van den Berg (2002) Curr. Rheumatol. Rep. 4:232).
[0160] Examples of animal models which can be used for evaluating the therapeutic efficacy of antibodies or antigen-binding fragments of the invention for preventing or treating inflammatory bowel disease (IBD) include TNBS-induced IBD, DSS-induced IBD, and (Padol et al. (2000) Eur. J. Gastrolenterol. Hepatol. 12:257; Murthy et al. (1993) Dig. Dis. Sci. 38:1722).
[0161] Examples of animal models which can be used for evaluating the therapeutic efficacy of antibodies or antigen-binding fragments of the invention for preventing or treating glomerulonephritis include anti-GBM-induced glomerulonephritis (Wada et al. (1996) Kidney Int. 49:761-767) and anti-thyl-induced glomerulonephritis (Schneider et al. (1999) Kidney Int. 56:135-144).
[0162] Examples of animal models which can be used for evaluating the therapeutic efficacy of antibodies or antigen-binding fragments of the invention for preventing or treating multiple sclerosis include experimental autoimmune encephalomyelitis (EAE) (Link and Xiao (2001) Immunol. Rev. 184:117-128).
[0163] Animal models can also be used for evaluating the therapeutic efficacy of antibodies or antigen-binding fragments of the invention for preventing or treating CD154-related conditions, such as systemic erythematosus lupus (SLE), for example using the MRL-Faslpr mice (Schneider, supra; Tesch et al. (1999) J. Exp. Med. 190).
7. Treatment Regimes and Dosages
[0164] In prophylactic applications, pharmaceutical compositions or medicaments are administered to a subject suffering from a disorder treatable with a polypeptide having an Fc region, for example, an immune system disorder, in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the outset of the disorder, including biochemical, histologic and/or behavioral symptoms of the disorder, its complications and intermediate pathological phenotypes presenting during development of the disorder. In therapeutic applications, compositions or medicaments are administered to a subject suspected of, or already suffering from such a disorder in an amount sufficient to cure, or at least partially arrest, the symptoms of the disorder (biochemical, histologic and/or behavioral), including its complications and intermediate pathological phenotypes in development of the disorder. The polypeptides of the invention are particularly useful for modulating the biological activity of a cell surface antigen that resides in the blood, where the disease being treated or prevented is caused at least in part by abnormally high or low biological activity of the antigen.
[0165] In some methods, administration of agent reduces or eliminates the immune disorder, for example, inflammation, such as associated with CD154 activity. An amount adequate to accomplish therapeutic or prophylactic treatment is defined as a therapeutically- or prophylactically-effective dose. In both prophylactic and therapeutic regimes, agents are usually administered in several dosages until a sufficient immune response has been achieved.
[0166] Effective doses of the compositions of the present invention, for the treatment of the above described conditions vary depending upon many different factors, including means of administration, target site, physiological state of the subject, whether the subject is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the subject is a human but non-human mammals including transgenic mammals can also be treated.
[0167] For passive immunization with an antibody, the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 20 mg/kg, of the host body weight. For example dosages can be 1 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg, preferably at least 1 mg/kg. Subjects can be administered such doses daily, on alternative days, weekly or according to any other schedule determined by empirical analysis. An exemplary treatment entails administration in multiple dosages over a prolonged period, for example, of at least six months. Additional exemplary treatment regimes entail administration once per every two weeks or once a month or once every 3 to 6 months. Exemplary dosage schedules include 1-10 mg/kg or 15 mg/kg on consecutive days, 30 mg/kg on alternate days or 60 mg/kg weekly. In some methods, two or more monoclonal antibodies with different binding specificities are administered simultaneously, in which case the dosage of each antibody administered falls within the ranges indicated.
[0168] Antibody is usually administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. In some methods, dosage is adjusted to achieve a plasma antibody concentration of 1-1000 μg/ml and in some methods 25-300 μg/ml. Alternatively, antibody can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the antibody in the subject. In general, human antibodies show the longest half-life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies.
[0169] The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, compositions containing the present antibodies or a cocktail thereof are administered to a subject not already in the disease state to enhance the subject's resistance. Such an amount is defined to be a “prophylactic effective dose.” In this use, the precise amounts again depend upon the subject's state of health and general immunity, but generally range from 0.1 to 25 mg per dose, especially 0.5 to 2.5 mg per dose. A relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some subjects continue to receive treatment for the rest of their lives.
[0170] In therapeutic applications, a relatively high dosage (e.g., from about 1 to 200 mg of antibody per dose, with dosages of from 5 to 25 mg being more commonly used) at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the subject shows partial or complete amelioration of symptoms of disease. Thereafter, the patent can be administered a prophylactic regime.
[0171] Doses for nucleic acids encoding antibodies range from about 10 ng to 1 g, 100 ng to 100 mg, 1 μg to 10 mg, or 30-300 μg DNA per subject. Doses for infectious viral vectors vary from 10-100, or more, virions per dose.
[0172] Therapeutic agents can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intracranial, intraperitoneal, intranasal or intramuscular means for prophylactic and/or therapeutic treatment. The most typical route of administration of a protein drug is intravascular, subcutaneous, or intramuscular, although other routes can be effective. In some methods, agents are injected directly into a particular tissue where deposits have accumulated, for example intracranial injection. In some methods, antibodies are administered as a sustained release composition or device, such as a Medipad™ device. The protein drug can also be administered via the respiratory tract, e.g., using a dry powder inhalation device.
[0173] Agents of the invention can optionally be administered in combination with other agents that are at least partly effective in treatment of immune disorders.
8. Pharmaceutical Compositions
[0174] The therapeutic compositions of the invention include at least one aglycosylated antibody or antibody fragment of the invention in a pharmaceutically acceptable carrier. A “pharmaceutically acceptable carrier” refers to at least one component of a pharmaceutical preparation that is normally used for administration of active ingredients. As such, a carrier may contain any pharmaceutical excipient used in the art and any form of vehicle for administration. The compositions may be, for example, injectable solutions, aqueous suspensions or solutions, non-aqueous suspensions or solutions, solid and liquid oral formulations, salves, gels, ointments, intradermal patches, creams, lotions, tablets, capsules, sustained release formulations, and the like. Additional excipients may include, for example, colorants, taste-masking agents, solubility aids, suspension agents, compressing agents, enteric coatings, sustained release aids, and the like.
[0175] Agents of the invention are often administered as pharmaceutical compositions comprising an active therapeutic agent, i.e., and a variety of other pharmaceutically acceptable components. See Remington's Pharmaceutical Science (15th ed., Mack Publishing Company, Easton, Pa. (1980)). The preferred form depends on the intended mode of administration and therapeutic application. The compositions can also include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like.
[0176] Antibodies can be administered in the form of a depot injection or implant preparation, which can be formulated in such a manner as to permit a sustained release of the active ingredient. An exemplary composition comprises monoclonal antibody at 5 mg/mL, formulated in aqueous buffer consisting of 50 mM L-histidine, 150 mM NaCl, adjusted to pH 6.0 with HCl.
[0177] Typically, compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The preparation also can be emulsified or encapsulated in liposomes or micro particles such as polylactide, polyglycolide, or copolymer for enhanced adjuvant effect, as discussed above (see Langer, Science 249: 1527 (1990) and Hanes, Advanced Drug Delivery Reviews 28:97 (1997)).
9. Monitoring the Course of Treatment
[0178] Treatment of a subject suffering from a disease or disorder, such as an immune disorder, can be monitored using standard methods. Some methods entail determining a baseline value, for example, of an antibody level or profile in a subject, before administering a dosage of agent, and comparing this with a value for the profile or level after treatment. A significant increase (i.e., greater than the typical margin of experimental error in repeat measurements of the same sample, expressed as one standard deviation from the mean of such measurements) in value of the level or profile signals a positive treatment outcome (i.e., that administration of the agent has achieved a desired response). If the value for immune response does not change significantly, or decreases, a negative treatment outcome is indicated.
[0179] In other methods, a control value (i.e., a mean and standard deviation) of level or profile is determined for a control population. Typically the individuals in the control population have not received prior treatment. Measured values of the level or profile in a subject after administering a therapeutic agent are then compared with the control value. A significant increase relative to the control value (e.g., greater than one standard deviation from the mean) signals a positive or sufficient treatment outcome. A lack of significant increase or a decrease signals a negative or insufficient treatment outcome. Administration of agent is generally continued while the level is increasing relative to the control value. As before, attainment of a plateau relative to control values is an indicator that the administration of treatment can be discontinued or reduced in dosage and/or frequency.
[0180] In other methods, a control value of the level or profile (e.g., a mean and standard deviation) is determined from a control population of individuals who have undergone treatment with a therapeutic agent and whose levels or profiles have plateaued in response to treatment. Measured values of levels or profiles in a subject are compared with the control value. If the measured level in a subject is not significantly different (e.g., more than one standard deviation) from the control value, treatment can be discontinued. If the level in a subject is significantly below the control value, continued administration of agent is warranted. If the level in the subject persists below the control value, then a change in treatment may be indicated.
[0181] In other methods, a subject who is not presently receiving treatment but has undergone a previous course of treatment is monitored for antibody levels or profiles to determine whether a resumption of treatment is required. The measured level or profile in the subject can be compared with a value previously achieved in the subject after a previous course of treatment. A significant decrease relative to the previous measurement (i.e., greater than a typical margin of error in repeat measurements of the same sample) is an indication that treatment can be resumed. Alternatively, the value measured in a subject can be compared with a control value (mean plus standard deviation) determined in a population of subjects after undergoing a course of treatment. Alternatively, the measured value in a subject can be compared with a control value in populations of prophylactically treated subjects who remain free of symptoms of disease, or populations of therapeutically treated subjects who show amelioration of disease characteristics. In all of these cases, a significant decrease relative to the control level (i.e., more than a standard deviation) is an indicator that treatment should be resumed in a subject.
[0182] The antibody profile following administration typically shows an immediate peak in antibody concentration followed by an exponential decay. Without a further dosage, the decay approaches pretreatment levels within a period of days to months depending on the half-life of the antibody administered. For example the half-life of some human antibodies is of the order of 20 days.
[0183] In some methods, a baseline measurement of antibody to a given antigen in the subject is made before administration, a second measurement is made soon thereafter to determine the peak antibody level, and one or more further measurements are made at intervals to monitor decay of antibody levels. When the level of antibody has declined to baseline or a predetermined percentage of the peak less baseline (e.g., 50%, 25% or 10%), administration of a further dosage of antibody is administered. In some methods, peak or subsequent measured levels less background are compared with reference levels previously determined to constitute a beneficial prophylactic or therapeutic treatment regime in other subjects. If the measured antibody level is significantly less than a reference level (e.g., less than the mean minus one standard deviation of the reference value in population of subjects benefiting from treatment) administration of an additional dosage of antibody is indicated.
[0184] Additional methods include monitoring, over the course of treatment, any art-recognized physiologic symptom (e.g., physical or mental symptom) routinely relied on by researchers or physicians to diagnose or monitor disorders.
[0185] The following examples are included for purposes of illustration and should not be construed as limiting the invention.
EXEMPLIFICATION
[0186] Throughout the examples, the following materials and methods were used unless otherwise stated.
Materials and Methods
[0187] In general, the practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, recombinant DNA technology, immunology (especially, e.g., antibody technology), and standard techniques in electrophoresis. See, e.g., Sambrook, Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory Press (1989); Antibody Engineering Protocols (Methods in Molecular Biology), 510, Paul, S., Humana Pr (1996); Antibody Engineering: A Practical Approach (Practical Approach Series, 169), McCafferty, Ed., Irl Pr (1996); Antibodies: A Laboratory Manual, Harlow et al., C.S.H.L. Press, Pub. (1999); and Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons (1992).
Production of the Modified Antibodies
[0188] For producing the modified antibodies of the invention, polynucleotides encoding either a model human antibody (hu5c8), variant antibodies thereof, or corresponding Fc regions, were introduced into standard expression vectors. The human antibody hu5c8 and variants thereof are described in, e.g., U.S. Pat. Nos. 5,474,771 and 6,331,615. The cDNA sequence and amino acid sequence are provided in the sequence listing for, respectively, the hu5c8 IgG1 heavy chain (SEQ ID NOS: 1-2), hu5c8 light chain (SEQ ID NOS: 3-4), hu5c8 IgG1 Fc region (SEQ ID NOS: 5-6), hu5C8 IgG4 heavy chain (SEQ ID NOS: 7-8), hu5c8 IgG4 variant (S228P) (SEQ ID NOS: 9-10), and hu5c8 IgG4 variant (S228P/T299A) (SEQ ID NOS: 11-12). Vectors where then introduced into EBNA 293 cells using large-scale transient transfection techniques. The transfected 293 cells were cultured using standard media and incubation conditions. Cells were typically refed after 1 day post-transfection and then allowed to express and secrete the recombinant protein for 1 to 3 days. Culture media containing the secreted recombinant antibodies or Fc regions were then harvested for purification.
Purification of the Modified Antibodies
[0189] For performing antibody purification, recombinant aglycosylated antibodies produced in eukaryotic cells were harvested from the cell culture medium and subjected to the following chromatography techniques. In particular, recombinant Protein A columns (5 mL) were prepared and washed with 100 mL 0.1 N NaOH and then equilibrated with PBS until neutralized. The conditioned media (˜1.5 L) was then pumped through the column at 10 mL/min. After loading, the column was washed with 100 mL 3×PBS and then 10 mL 1×PBS. The antibodies were eluted with 1.3 mL fractions of 100 mM NaH2PO4, pH 2.8 into collection tubes containing 0.3 mL 1 M HEPES, pH 8 for immediate neutralization. Fractions containing the eluted antibodies were identified by monitoring the concentration using light absorbance (A280) of 1:10 dilutions of each fraction. This purification step was scaled up or down proportionately to the scale of the transient transfection.
[0190] Resultant Protein A pools were further purified by chromatography on a 1.6 mL Poros HS column. The recombinant protein pools (˜8 mL) were diluted ten-fold with 25 mM NaAcetate, pH 4.5 and half was loaded in each of two purification runs using a BioCad HPLC. The proteins were loaded at a flow rate of 5 mL/min, the column washed with 10 column volumes of the dilution buffer and then eluted with a 25 column volume gradient of 0 to 1 M NaCl in the dilution buffer. Fractions of 0.8 mL were collected and monitored for protein concentration by light absorbance (A280).
[0191] Alternatively, the resultant Protein A pool from a small scale preparation was purified by Protein L chromatography. A Protein L column (1 mL) was prepared and washed with 10 mL 0.1 N NaOH and then equilibrated with PBS until neutralized. The neutralized Protein A pool (3 mL) was then loaded in 1 mL aliquots. After loading, the column was washed with 10 mL 3×PBS and then 10 mL 1×PBS. The antibodies were eluted with 0.4 mL fractions of 100 mM NaH2PO4, pH 2.8 into collection tubes containing 0.1 mL 1 M HEPES, pH 8 for immediate neutralization. Fractions containing the eluted antibodies were identified by monitoring the concentration using light absorbance (A280) of 1:5 dilutions of each fraction.
[0192] In addition to light absorbance, eluants containing recombinant protein were also monitored with a refractive index detector (Waters) and a Precision Detector PD2020 light scattering instrument. Molecular weights were calculated with the Precision Detector software. All variant antibodies (four forms of hu5c8) eluted identically from the SEC column, showing a single major peak with a minor amount of higher molecular weight material (dimer). A molecular weight of 148,300 was determined by light scattering for the main peak of the T299C hu5c8 variant. Size exclusion chromatography of the huIgG1 Fc variants was carried out identically to the full length antibodies. All four Fc proteins ran identically, giving a major peak with calculated MWs ranging from 53,000 to 55,000 Daltons. Finally, recombinant protein samples were obtained, dialyzed against PBS, sterile filtered, and stored at 4° C. in 10 mg aliquots until needed for further analysis.
SDS-PAGE
[0193] For performing SDS-PAGE, protein samples were typically diluted to 200 μg/mL in Laemmli SDS-PAGE sample buffer containing either 25 mM DTT for reducing conditions, or 25 mM NEM for non-reducing conditions. Aliquots of 2.5 and 10 μl were loaded on 4-20% gradient gels.
Mass Spectrometry
[0194] For performing mass spectroscopy, protein samples were reduced in 9 mM DTT, at pH 7.8, prior to analysis. The samples were desalted over a C4 guard column and analyzed on-line by ESMS using a triple quadrupole instrument. The ESMS raw data were deconvoluted by the MaxEnt program to generate zero charged mass spectra. This procedure allows for multiple charged signals to collapse into one peak for molecular mass determinations.
Pegylation
[0195] For performing pegylation of the aglycosylated polypeptides of the invention, aliquots of 50 μL of 0.94 mg/mL solutions of the T299A and T299C variant Fc were first precipitated with 1 mL ethanol at −20° C. overnight. Resultant precipitates were then pelleted and the ethanol removed and 50 μL of a solution of 6.4 M urea, 2% SDS and 10 mM EDTA, pH 8 was added and the solution heated to 100° C. for 5 min. For reduction, half the samples were treated with 4 mM TCEP for 30 min at room temperature. Aliquots of 5 μL of 1 M MES buffer at pH 6.5 were then added followed by either 50 μL H2O or a 5 mM solution of PEG (5K)-maleimide. After 30 min at room temperature, 10 μL aliquots of a 4× solution of Laemmli SDS-PAGE sample buffer was added to 30 μL of the reaction mixtures and the solution heated to 100° C. for 5 min. Then 5 and 15 μL aliquots of recombinant protein were loaded on 4-20% gradient gels for a determination of relative amounts of pegylation that occurred.
Example 1
Methods for Producing and Characterizing Aglycosylated Antibodies
[0196] The following example describes the production of an aglycosylated antibody in a eukaryotic cell and the characterization of the resultant antibody.
[0197] Nucleic acids encoding a model human antibody (hu5c8) of the IgG1 subtype having binding affinity for the CD154 ligand were genetically engineered to have one of several alterations. The first alteration comprised a codon encoding in place of the wild type amino acid residue, i.e., threonine, at position 299, an alanine (T299A). In another alteration, the codon encoding threonine at position 299 was changed to encode a cysteine (T299A). A control alteration was also included, in which the specific asparagine that is glycosylated is mutated (N297Q) (FIGS. 3 , 5-7). In addition, the T299A mutation was introduced into a model human antibody hu5C8 of the IgG4 subtype. The IgG4 sequence had a further modification in the hinge peptide (S228P) to stabilize the interchain disulfides, an issue unrelated to the aglycosyl modification (FIG. 4 ). Each alteration was incorporated into an expression vector and introduced into a eukaryotic cell line using the methods described herein. In addition, the forgoing alterations where also tested in the context of an Fc region unlinked from the corresponding variable region. Each modified antibody, or Fc fragment thereof, along with a corresponding control antibody or antibody fragment, was then expressed in cell culture, harvested from the cell culture media, and purified using standard techniques. Each antibody or antibody fragment was then characterized for its aglycosylation and binding activity.
[0198] The aglycosylation for each antibody or antibody fragment was characterized using standard gel electrophoresis and chromatography techniques. In particular, reducing and non-reducing SDS-PAGE and size exclusion chromatography under native conditions were performed and demonstrated that the T299A and T299C variants of test antibody (hu5c8) and fragments thereof, i.e., huIgG1 Fc, were of the expected molecular size and subunit organization. The absence of glycosylation of the T299A and T299C antibody variants was indicated by the more rapid migration of the heavy chain of the proteins on reducing SDS-PAGE (FIG. 3 ). In addition, mass spectrometry under reducing conditions confirmed the expected mass of the constructs and the absence of glycans in the T299A and T299C variants (FIGS. 8-11 ). Mass spectroscopy under non-reducing conditions also demonstrated the presence of cysteine adducts on the huIgG1 T299C Fc variants (FIGS. 8-11 ).
[0199] The mass of the T299A variant corresponded to the predicted protein dimer (expected, 51,824.7, found, 51,826). In contrast the mass of the T299C variant was 246 Daltons larger that predicted (expected 51,886, found 52,132) (FIG. 3 ). This would correspond to the addition of two cysteine adducts to the Fc dimer (2×120=240) (FIG. 5 ).
[0200] Accordingly, it was concluded that the alteration of the first amino acid proximal to a glycosylation motif inhibited the glycosylation of the antibody at second amino acid residue thereby providing an efficient and reliable approach for producing aglycosylated antibodies in eukaryotic cells.
Example 2
Methods for Producing an Aglycosylated Antibody with Reduced Effector Function Using Amino Acid Substitutions of Sufficient Steric Bulk and/or Charge
[0201] The following example describes the production of an aglycosylated antibody by altering an antibody at a first amino acid residue with a residue that has sufficient steric bulk and/or charge as to inhibit glycosylation.
[0202] Nucleic acids encoding a candidate antibody, for example, an antibody of the IgG1 or IgG4 subtype, were genetically engineered to have one of several alterations predicted to inhibit glycosylation and/or effector function. While not wishing to be bound by theory, results obtained above for a cysteine adduct support the rationale that a sufficiently bulky and/or charged residue will inhibit a glycosidase from glycosylating an Fc-containing polypeptide and reduce undesired effector function. For example, a substitution at the Kabat position of 299 (e.g., T299) with a bulky or charged residue is predicted to inhibit a glycosidase from glycosylating the antibody at, for example, position 297. In addition, such an amino acid substitution is also predicted to modulate the binding of the antibody to an Fc receptor. In the bound complex between an antibody Fc region and an Fc receptor, for example, the FcγIIIb receptor, the residue T299 of the antibody Fc region is located very close to the binding interface with the FcγIIIb receptor. In particular, the distances of the side chain chemistry of the T299 residue to the Y150 and H152 residues of the FcγIIIb receptor are 4.2 Å and 5.6 Å, respectively. Thus, by substituting T299 for a residue with sufficient steric bulk, such as F, H, Q, W, or Y, the antibody will not only be aglycosylated but also have reduced Fc binding affinity to the Fc receptor due to unfavorable steric interactions.
[0203] Still further, the inhibition of glycosylation and Fc binding can be modulated by substituting T299 with a charged side chain chemistry such as D, E, K, or R. The resulting antibody variant will not only have reduced glycosylation but also reduced Fc binding affinity to an Fc receptor due to unfavorable electrostatic interactions.
[0204] Accordingly, modifying a first amino acid residue side chain chemistry to one of sufficient steric bulk and/or charge, is predicted to inhibit the glycosylation of the antibody at a second amino acid residue as well as reduce Fc binding to an Fc receptor. Thus, the invention provides an efficient and reliable approach for producing aglycosylated antibodies with reduced effector function in eukaryotic cells.
Example 3
Methods for Pegylating Aglycosylated Antibodies
[0205] The following example describes the production of an aglycosylated antibody in a eukaryotic cell and the pegylation of the resultant antibody.
[0206] In particular, the T299C antibody variant was determined to be specifically modified with Peg-maleimide under non-denaturing conditions by first reducing the protein with TCEP to remove the cysteine adduct, allowing the hinge disulfides to reform by dialyzing the protein over several days, and reacting with PEG-maleimide. The T299A antibody variant could not be modified with PEG under these conditions (FIG. 6 ).
[0207] Briefly, to reduce the test proteins, 200 μL of the 0.94 mg/mL T299A and T299C Fc antibody variant preparations were treated with 4 μL of 500 mM EDTA, pH 8 (final concentration 10 mM) and 10 μL of 100 mM TCEP (final concentration 5 mM) for 3 hours at room temperature. The reduced proteins were dialyzed against PBS over four days with five changes at 1:1000 volume ratios. Aliquots (5 μL) of the protein preparations were then treated with 5 μL of 5 mM PEG-maleimide (5,000 mw) under non-denaturing conditions for 1 h and then prepared for SDS-PAGE by the addition of 5 μL of 4× Laemmli SDS-PAGE sample buffer contained 100 mM DTT. Only the T299C antibody variant was observed to have a PEG adduct (FIG. 7 ).
[0208] Corroboration that the T299C cysteine had formed a cystine disulfide bond was obtained by attempting to react the Fc with the thiol-specific modifying reagent, PEG-maleimide. Under denaturing (6.4 M urea, 2% SDS), but non-reducing conditions, no reaction occurred with the PEG-maleimide. Under reducing conditions the T299C variant did react with the PEG-maleimide, yielding a larger product than the T299A variant, indicating the presence of the extra cysteine (FIG. 3 ).
[0209] Accordingly, it was concluded that the alteration of the first amino acid proximal to a glycosylation motif capable of inhibiting the glycosylation of the antibody at a second amino acid residue, when altered to a cysteine residue, also provided for an efficient and reliable pegylation residue.
Example 4
Methods for Determining Altered Effector Function of Aglycosylated Antibodies
[0210] The following example describes assays for determining the altered effector function of the aglycosylated antibodies of the invention.
[0211] The effector function of the aglycosylated variant antibodies of the invention were characterized by their ability to bind an antigen and also bind an Fc receptor or a complement molecule such as C1q. In particular, the FcγR binding affinities were measured with assays based on the ability of the antibody to form a “bridge” between the CD154 antigen and a cell bearing an Fc receptor. The C1q binding affinity was measured based on the ability of the antibody to form a “bridge” between the CD154 antigen and C1q (FIGS. 14-15 ).
[0212] Briefly, the FcγR bridging assay was performed by coating 96 well Maxisorb ELISA plates (Nalge-Nunc Rochester, N.Y., USA) with recombinant soluble human CD154 ligand (i.e., at a concentration of 1 μg/ml overnight at 4° C. in PBS; Karpusas, Hsu et al. 1995). Titrations of glycosylated or aglycosylated forms of anti-CD154 antibody (hu5c8) were then bound to CD154 for 30 minutes at 37° C., the plates were then washed, and the binding of fluorescently labeled U937 (CD64+) cells was measured. The U937 cells were grown in RPMI medium with 10% FBS, 10 mM HEPES, L-glutamine, and penicillin/streptomycin, split 1:2, and activated for one day prior to the assay with 1000 units/ml of IFNγ to increase Fc receptor (FcγRI) expression.
[0213] In another variation of the assay, the ability of the antibodies of the invention to bind to, or rather, fail to bind, to yet another Fc receptor, in particular, FcγRIII (CD16) was performed using the above bridging assay against fluorescently labeled human T cells (Jurkat cells) transfected with a CD16 expression construct. The ligand was produced by a monolayer of CD154-expressing Chinese Hamster Ovary (CHO) cells grown in 96 well tissue culture plates (Corning Life Sciences Acton, Mass., USA). The CHO-CD154+ cells were seeded into 96 well plates at 1×105 cells/ml and grown to confluency in α−MEM with 10% dialyzed FBS, 100 nM methotrexate, L-glutamine, and penicillin/streptomycin (Gibco-BRL Rockville, Md., USA). The CD16+Jurkat cells were grown in RPMI with 10% FBS, 400 μg/ml Geneticin, 10 mM HEPES, sodium pyruvate, L-glutamine, and penicillin/streptomycin (Gibco-BRL) and split 1:2 one day prior to performing the assay.
[0214] In the assays for both receptors, the Fc receptor-bearing cells were labeled with 2′,7′-bis-(2-carboxyethyl)-5-(and -6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) (Molecular Probes Eugene, Oreg., USA) for 20 minutes at 37° C. After washing to remove excess label, 1×105 of the labeled cells were incubated in the assay for 30 minutes at 37° C. Unbound FcγR positive cells were removed by washing several times and plates were read on a microplate reader (Cytofluor 2350 Fluorescent Microplate Reader, Millipore Corporation Bedford, Mass., USA) at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.
[0215] In each bridging assay, a reduced effector function of the aglycosylated IgG1 antibody variants of the invention as a function of FcγRI (upper panel) or FcγRIII (lower) binding was observed (FIGS. 12-13 ). In particular, the T299C variant, which is both aglycosylated and capable of forming a cysteine adduct was observed to have less effector function (FcγRI binding) as compared to merely aglycosylated antibodies (FIG. 12 upper panel). The aglycosyl IgG4 T299A antibody variant was also found to have exceptionally low binding to FcRγI, lower than the IgG1 T299A variant. This was not expected since the glycosylated IgG1 and IgG4 antibodies show similar binding in this assay (FIG. 13 ).
[0216] The C1q binding assay was performed by coating 96 well Maxisorb ELISA plates (Nalge-Nunc Rochester, N.Y., USA) with 50 μl recombinant soluble human CD154 ligand (Karpusas et al. Structure, 15; 3(12):1426 (1995) at 10 μg/ml overnight at 4° C. in PBS. The wells were aspirated and washed three times with wash buffer (PBS, 0.05% Tween 20) and blocked for ≧1 h with 200 μl/well of block/diluent buffer (0.1 M Na2HPO4, pH 7, 0.1 M NaCl, 0.05% Tween 20, 0.1% gelatin). The antibody to be tested was diluted in block/diluent buffer starting at 15 μg/ml with 3-fold dilutions. 50 μl were added per well, and the plates incubated for 2 h at room temperature. After aspirating and washing as above, 50 μl/well of 2 μg/ml of Sigma human C1q (C0660) diluted in block/diluent buffer was added and incubated for 1.5 h at room temperature. After aspirating and washing as above, 50 μl/well of sheep anti C1q (Serotec AHP033), diluted 3,560-fold in block/diluent buffer, was added. After incubation for 1 h at room temperature, the wells were aspirated and washed as above. 50 μl/well of donkey anti-sheep IgG HRP conjugate (Jackson ImmunoResearch 713-035-147) diluted to 1:10,000 in block/diluent was then added, and the wells incubated for 1 h at room temperature. After aspirating and washing as above, 100 μl TMB substrate (420 μM TMB, 0.004% H2O2 in 0.1 M sodium acetate/citric acid buffer, pH 4.9) was added and incubated for 2 min before the reaction was stopped with 100 μl 2 N sulfuric acid. The absorbance was read at 450 nm with a Softmax PRO instrument, and Softmax software was used to determine the relative binding affinity (C value) with a 4-parameter fit.
[0217] As shown in FIGS. 14-15 , the T299C mutant had a C1q binding affinity that was not only below the hu5c8 antibody but below that of the aglycosylated N297Q and T299A variants, which indicates that the mutation to cysteine was unexpectedly beneficial. The IgG4 T299A mutant showed no binding to C1q, similarly to the aglycosylated IgG4.
[0218] Accordingly, it was concluded that the alteration of a first amino acid proximal to a glycosylation motif inhibited the glycosylation of the antibody at a second amino acid residue, and when the first amino acid was a cysteine residue, the antibody had more reduced effector function. In addition, inhibition of glycosylation of an antibody of the IgG4 subtype had a more profound affect on FcγRI binding than expected.
EQUIVALENTS
[0219] For one skilled in the art, using no more than routine experimentation, there are many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
The invention claimed is:
1. A variant polypeptide of a parent polypeptide comprising an Fc region, wherein the Fc region of the variant polypeptide comprises a modified first amino acid residue at T299 of the Fc region according to the Kabat numbering system of IgG immunoglobulins, the modified first amino acid residue having a side chain chemistry selected from the group consisting of a side chain chemistry comprising a cysteine thiol, a side chain chemistry of sufficient steric bulk such that the polypeptide displays reduced effector function, and a side chain chemistry of sufficient electrostatic charge such that the polypeptide displays reduced effector function, and a second amino acid residue at N297 of the Fc region according to the Kabat numbering system of IgG immunoglobulins, the second amino acid having reduced glycosylation, wherein the variant polypeptide has reduced effector function as compared to the parent polypeptide.
2. The variant polypeptide of claim 1, wherein the side chain chemistry of the modified first amino acid residue comprises a cysteine thiol.
3. The variant polypeptide of claim 1, wherein the side chain chemistry is of sufficient steric bulk such that the polypeptide displays reduced effector function.
4. The variant polypeptide of claim 3, wherein the side chain chemistry of sufficient steric bulk is that of an amino acid residue selected from the group consisting of Phe, Trp, His, Glu, Gln, Arg, Lys, Met, and Tyr.
5. The variant polypeptide of claim 1, wherein the side chain chemistry is of sufficient electrostatic charge such that the variant polypeptide displays reduced effector function.
6. The variant polypeptide of claim 5, wherein the side chain chemistry is that of an amino acid residue selected from the group consisting of Asp, Glu, Lys, Arg, and His.
7. The variant polypeptide of claim 1, wherein the reduced effector function is reduced binding to an Fc receptor (FcR).
8. The variant polypeptide of claim 7, wherein the binding is reduced by a factor selected from the group consisting of about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 15-fold, about 50-fold, and about 100-fold.
9. The variant polypeptide of claim 7, wherein the Fc receptor (FcR) is selected from the group consisting of FcγRI, FcγRII, and FcγRIII.
10. The variant polypeptide of 1, wherein the reduced effector function is reduced binding to a complement protein.
11. The variant polypeptide of claim 10, wherein the complement protein is C1q.
12. The variant polypeptide of claim 10, wherein the reduced binding to a complement protein is by a factor selected from the group consisting of about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, and about 15-fold.
13. The polypeptide of claim 1, wherein the first amino acid residue is modified by substitution by a replacement amino acid.
14. The variant polypeptide of claim 13, wherein the replacement amino acid is a non-traditional amino acid residue.
15. The variant polypeptide of claim 1, wherein the first amino acid residue is capable of being linked to a functional moiety.
16. The variant polypeptide of claim 15, wherein the functional moiety is selected from the group consisting of a blocking moiety, a detectable moiety, a diagnostic moiety, and a therapeutic moiety.
17. The variant polypeptide of claim 16, wherein the blocking moiety is selected from the group consisting of a cysteine adduct, mixed disulfide, polyethylene glycol, and polyethylene glycol maleimide.
18. The variant polypeptide of claim 16, wherein the detectable moiety is selected from the group consisting of a fluorescent moiety and isotopic moiety.
19. The variant polypeptide of claim 16, wherein the diagnostic agent is capable of revealing the presence of a disease or disorder.
20. The variant polypeptide of claim 16, wherein the therapeutic moiety is selected from the group consisting of an anti-inflammatory agent, an anticancer agent, an anti-neurodegenerative agent, and an anti-infective agent.
21. A variant polypeptide of a parent polypeptide comprising an IgG1 Fc region, wherein the Fc region of the variant polypeptide comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent polypeptide, wherein the amino acid at position 299 of the parent polypeptide is threonine and the amino acid at position 299 of the variant polypeptide is selected from the group consisting of alanine, asparagine, glycine, tyrosine, cysteine, histidine, glutamic acid, aspartic acid, lysine, arginine, isolucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine, and wherein the variant polypeptide comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.
22. The variant polypeptide of claim 21, wherein the amino acid at position 299 is a cysteine.
23. The variant polypeptide of claim 1, wherein the polypeptide is pegylated at the modified first amino acid residue.
24. The variant polypeptide of claim 2, wherein the polypeptide is pegylated with PEG-maleimide.
25. The variant polypeptide of claim 1, wherein the modified first amino acid residue is a cysteine residue modified by a cysteine or mixed disulfide adduct.
26. The variant polypeptide of claim 1, wherein the polypeptide is an antibody variant.
27. The variant polypeptide of claim 1, wherein the Fc region is obtained from an antibody of an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
28. The variant polypeptide of claim 1, wherein the polypeptide binds to an antigen selected from the group consisting of a ligand, cytokine, receptor, cell surface antigen, and cancer cell antigen.
29. The polypeptide of claim 21, wherein the amino acid at position 299 is an alanine.
30. A composition comprising the variant polypeptide of claim 29 in a suitable pharmaceutical carrier.
31. An antibody variant of a parent antibody, wherein the antibody variant comprises an Fc region comprising a replacement amino acid substituted for the threonine at position 299 of the Fc region according to the Kabat numbering system for IgG immunoglobulins, the substituted amino acid residue having a side chain chemistry selected from the group consisting of a side chain chemistry comprising a cysteine thiol, a side chain chemistry of sufficient steric bulk such that the polypeptide displays reduced effector function, and a side chain chemistry of sufficient electrostatic charge such that the polypeptide displays reduced effector function and a second amino acid residue at N297 of the Fc region according to the Kabat numbering system for IgG immunoglobulins, the second amino acid residue having reduced glycosylation as compared to the parent antibody.
32. The antibody variant of claim 31, which has reduced effector function.
33. A varaint antibody of a parent antibody comprising an IgG1 Fc region, wherein the Fc region of the variant antibody comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent antibody, wherein the amino acid threonine at position 299 of the parent antibody is threonine and the amino acid at position 299 of the variant antibody is selected from the group consisting of alanine, asparagine, glycine, tyrosine, cysteine, histidine, glutamic acid, aspartic acid, lysine, arginine, isolucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine, and wherein the variant antibody comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.
34. The antibody variant of claim 31, wherein the Fc region is from an IgG1 antibody.
35. The antibody variant of claim 33, wherein the replacement amino acid residue at position 299 is an alanine.
36. The antibody variant of claim 33, wherein the replacement amino acid residue at position 299 is a cysteine.
37. The antibody variant of claim 31, wherein the Fc region is from an IgG4 antibody.
38. The antibody variant of claim 37, wherein the replacement amino acid at position 299 is a cysteine.
39. The antibody variant of claim 37, wherein the Fc region further comprises an amino acid at position 228 which differs from the amino acid at position 228 of the parent antibody, wherein the amino acid at position 228 of the parent antibody is a serine and the amino acid at position 228 of the variant antibody is a proline.
40. The antibody variant of claim 37, wherein the amino acid at position 299 is alanine.
41. The antibody variant of claim 33, wherein the amino acid at position 299 is asparagine.
42. The antibody variant of claim 37, wherein the amino acid at position 299 is asparagine.
43. The antibody variant of claim 33, wherein the amino acid at position 299 is glycine.
44. The antibody variant of claim 37, wherein the amino acid at position 299 is glycine.
45. The antibody variant of claim 33, wherein the amino acid at position 299 is tyrosine.
46. The antibody variant of claim 37, wherein the amino acid at position 299 is tyrosine.
47. The antibody variant of claim 33, wherein the amino acid at position 299 is histadine.
48. The antibody variant of claim 37, wherein the amino acid at position 299 is histadine.
49. The antibody variant of claim 33, wherein the amino acid at position 299 is glutamic acid.
50. The antibody variant of claim 37, wherein the amino acid at position 299 is glutamic acid.
51. The antibody variant of claim 33, wherein the amino acid at position 299 is aspartic acid.
52. The antibody variant of claim 37, wherein the amino acid at position 299 is aspartic acid.
53. The antibody variant of claim 33, wherein the amino acid at position 299 is lysine.
54. The antibody variant of claim 37, wherein the amino acid at position 299 is lysine.
55. The antibody variant of claim 33, wherein the amino acid at position 299 is arginine.
56. The antibody variant of claim 37, wherein the amino acid at position 299 is arginine.
57. The antibody variant of claim 33, wherein the amino acid at position 299 is isoleucine.
58. The antibody variant of claim 37, wherein the the amino acid at position 299 is isoleucine.
59. The antibody variant of claim 33, wherein the amino acid at position 299 is leucine.
60. The antibody variant of claim 37, wherein the amino acid at position 299 is leucine.
61. The antibody variant of claim 33, wherein the amino acid at position 299 is methionine.
62. The antibody variant of claim 37, wherein the amino acid at position 299 is methionine.
63. The antibody variant of claim 33, wherein the amino acid at position 299 is phenylalanine.
64. The antibody variant of claim 37, wherein the amino acid at position 299 is phenylalanine.
65. The antibody variant of claim 33, the amino acid at position 299 is proline.
66. The antibody variant of claim 37, wherein the amino acid at position 299 is proline.
67. The antibody variant of claim 33, wherein the amino acid at position 299 is tryptophan.
68. The antibody variant of claim 37, wherein the amino acid at position 299 is tryptophan.
69. The antibody variant of claim 33, wherein the amino acid at position 299 is valine.
70. The antibody variant of claim 37, wherein the amino acid at position 299 is valine.
71. The variant polypeptide of claim 21, wherein the amino acid at position 299 is asparagine.
72. The variant polypeptide of claim 21, wherein the amino acid at position 299 is glycine.
73. The variant polypeptide of claim 21, wherein the amino acid at position 299 is tyrosine.
74. The variant polypeptide of claim 21, wherein the amino acid at position 299 is histadine.
75. The variant polypeptide of claim 21, wherein the amino acid at position 299 is glutamic acid.
76. The variant polypeptide of claim 21, wherein the amino acid at position 299 is aspartic acid.
77. The variant polypeptide of claim 21, wherein the amino acid at position 299 is a lysine.
78. The variant polypeptide of claim 21, wherein the amino acid at position 299 is an arginine.
79. The variant polypeptide of claim 21, wherein the amino acid at position 299 is isoleucine.
80. The variant polypeptide of claim 21, wherein the amino acid at position 299 is leucine.
81. The variant polypeptide of claim 21, wherein the amino acid at position 299 is methionine.
82. The variant polypeptide of claim 21, wherein the amino acid at position 299 is phenylalanine.
83. The variant polypeptide of claim 21, wherein the amino acid at position 299 is proline.
84. The variant polypeptide of claim 21, wherein the amino acid at position 299 is tryptophan.
85. The variant polypeptide of claim 21, wherein the amino acid at position 299 is valine.
86. A composition comprising the antibody variant of claim 35 in a suitable pharmaceutical carrier.
87. A variant polypeptide of a parent polypeptide comprising an IgG 1 Fc region, wherein the Fc region of the variant polypeptide comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent polypeptide, wherein the amino acid at position 299 of the parent polypeptide is threonine and the amino acid at position 299 of the variant polypeptide is an alanine, and wherein the variant polypeptide comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.
88. A variant polypeptide of a parent polypeptide comprising an IgG4 Fc region, wherein the Fc region of the variant polypeptide comprises an amino acid at position 299 which differs from the amino acid at position 299 of the parent polypeptide, wherein the amino acid at position 299 of the parent polypeptide is threonine and the amino acid at position 299 of the variant polypeptide is an alanine, and wherein the variant polypeptide comprises an amino acid at position 297 of the Fc region having reduced glycosylation and displays reduced effector function as compared to the parent polypeptide.
Patent Citations (115)
| Patent | Date | Inventor | Cited By |
|---|---|---|---|
| US5585097(A) | 1996-12-01 | Bolt et al. | Applicant |
| US5624821(A) | 1997-04-01 | Winter et al. | Applicant |
| US5648260(A) | 1997-07-01 | Winter et al. | Applicant |
| US5714350(A) | 1998-02-01 | Co et al. | Applicant |
| US6165745(A) | 2000-12-01 | Ward et al. | Applicant |
| US6194551(B1) | 2001-02-01 | Idusogie et al. | Applicant |
| US6218149(B1) | 2001-04-01 | Morrison et al. | Applicant |
| US6277375(B1) | 2001-08-01 | Ward | Applicant |
| US6284536(B1) | 2001-09-01 | Morrison et al. | Applicant |
| US6350861(B1) | 2002-02-01 | Co et al. | Applicant |
| US6528624(B1) | 2003-03-01 | Idusogie et al. | Applicant |
| US6538124(B1) | 2003-03-01 | Idusogie et al. | Applicant |
| US6720165(B2) | 2004-04-01 | Nock et al. | Applicant |
| US6737056(B1) | 2004-05-01 | Presta | Applicant |
| US6821505(B2) | 2004-11-01 | Ward | Applicant |
| US6933368(B2) | 2005-08-01 | Co et al. | Applicant |
| US6979553(B2) | 2005-12-01 | Farinas et al. | Applicant |
| US7083784(B2) | 2006-08-01 | Dall'Acqua et al. | Applicant |
| US7183387(B1) | 2007-02-01 | Presta | Applicant |
| US7217797(B2) | 2007-05-01 | Hinton et al. | Applicant |
| US7217798(B2) | 2007-05-01 | Hinton et al. | Applicant |
| US7247302(B1) | 2007-07-01 | Rosok et al. | Applicant |
| US7297775(B2) | 2007-11-01 | Idusogie et al. | Applicant |
| US7317091(B2) | 2008-01-01 | Lazar et al. | Applicant |
| US7332581(B2) | 2008-02-01 | Presta | Applicant |
| US7335742(B2) | 2008-02-01 | Presta | Applicant |
| US7351803(B2) | 2008-04-01 | Johnson et al. | Applicant |
| US7355008(B2) | 2008-04-01 | Stavenhagen et al. | Applicant |
| US2002/0131968(A1) | 2002-09-01 | Waldmann et al. | Applicant |
| US2002/0147312(A1) | 2002-10-01 | O'Keefe et al. | Applicant |
| US2002/0193573(A1) | 2002-12-01 | Nock et al. | Applicant |
| US2003/0026692(A1) | 2003-02-01 | Lutz | Applicant |
| US2003/0073164(A1) | 2003-04-01 | Simmons et al. | Applicant |
| US2003/0158389(A1) | 2003-08-01 | Idusogie et al. | Applicant |
| US2004/0006216(A1) | 2004-01-01 | Waldmann et al. | Applicant |
| US2004/0010124(A1) | 2004-01-01 | Johnson et al. | Applicant |
| US2004/0091957(A1) | 2004-05-01 | Nock et al. | Applicant |
| US2004/0132101(A1) | 2004-07-01 | Lazar et al. | Examiner |
| US2004/0191244(A1) | 2004-09-01 | Presta | Applicant |
| US2004/0228856(A1) | 2004-11-01 | Presta | Applicant |
| US2005/0054832(A1) | 2005-03-01 | Lazar et al. | Applicant |
| US2005/0064514(A1) | 2005-03-01 | Stavenhagen et al. | Applicant |
| US2005/0118174(A1) | 2005-06-01 | Presta | Applicant |
| US2005/0170464(A1) | 2005-08-01 | Simmons et al. | Applicant |
| US2005/0215768(A1) | 2005-09-01 | Armour et al. | Applicant |
| US2005/0233382(A1) | 2005-10-01 | Presta | Applicant |
| US2005/0244403(A1) | 2005-11-01 | Lazar et al. | Applicant |
| US2006/0024298(A1) | 2006-02-01 | Lazar et al. | Applicant |
| US2006/0160996(A9) | 2006-07-01 | Lazar et al. | Applicant |
| US2006/0193856(A1) | 2006-08-01 | Taylor et al. | Applicant |
| US2006/0275283(A1) | 2006-12-01 | van Vlijmen et al. | Examiner |
| US2007/0092516(A1) | 2007-04-01 | Waldmann et al. | Applicant |
| US2007/0202098(A1) | 2007-08-01 | Lazar et al. | Applicant |
| US2007/0219133(A1) | 2007-09-01 | Lazar et al. | Applicant |
| US2007/0224189(A1) | 2007-09-01 | Lazar et al. | Applicant |
| US2007/0224192(A1) | 2007-09-01 | Lazar et al. | Applicant |
| US2007/0237767(A1) | 2007-10-01 | Lazar et al. | Applicant |
| US2007/0238665(A1) | 2007-10-01 | Lazar et al. | Applicant |
| US2007/0243188(A1) | 2007-10-01 | Lazar et al. | Applicant |
| US2007/0244303(A1) | 2007-10-01 | Johnson et al. | Applicant |
| US2007/0248602(A1) | 2007-10-01 | Lazar et al. | Applicant |
| US2007/0248603(A1) | 2007-10-01 | Lazar et al. | Applicant |
| US2008/0050371(A1) | 2008-02-01 | Johnson et al. | Applicant |
| US2008/0051563(A1) | 2008-02-01 | Lazar et al. | Applicant |
| US2008/0206867(A1) | 2008-08-01 | Desjarlais et al. | Applicant |
| US2009/0010920(A1) | 2009-01-01 | Lazar et al. | Applicant |
| US2009/0068175(A1) | 2009-03-01 | Lazar et al. | Applicant |
| EP255694(A1) | 1988-02-01 | Applicant | |
| WO-88/07089(A1) | 1988-09-01 | Applicant | |
| WO-89/07142(A1) | 1989-08-01 | Applicant | |
| WO-93/19196(A1) | 1993-09-01 | Applicant | |
| WO-93/22332(A1) | 1993-11-01 | Applicant | |
| WO-94/28027(A1) | 1994-12-01 | Applicant | |
| WO-94/29351(A2) | 1994-12-01 | Applicant | |
| WO-97/34631(A1) | 1997-09-01 | Applicant | |
| WO-98/05787(A1) | 1998-02-01 | Applicant | |
| WO-98/23289(A1) | 1998-06-01 | Applicant | |
| WO-98/47531(A2) | 1998-10-01 | Applicant | |
| WO-99/22764(A1) | 1999-05-01 | Applicant | |
| WO-99/51642(A1) | 1999-10-01 | Applicant | |
| WO-99/54484(A1) | 1999-10-01 | Applicant | |
| WO-99/58572(A1) | 1999-11-01 | Applicant | |
| WO-00/05268(A1) | 2000-02-01 | Applicant | |
| WO-00/42072(A2) | 2000-07-01 | Applicant | |
| WO-02/060919(A2) | 2002-08-01 | Applicant | |
| WO-02/062850(A2) | 2002-08-01 | Applicant | |
| WO-02/066514(A2) | 2002-08-01 | Applicant | |
| WO-02/079232(A2) | 2002-10-01 | Applicant | |
| WO-03/001870(A2) | 2003-01-01 | Applicant | |
| WO-03/026692(A2) | 2003-04-01 | Applicant | |
| WO-03/035835(A2) | 2003-05-01 | Applicant | |
| WO-03/059282(A2) | 2003-07-01 | Applicant | |
| WO-03/074679(A2) | 2003-09-01 | Applicant | |
| WO-03/101485(A1) | 2003-12-01 | Applicant | |
| WO-2004/029207(A2) | 2004-04-01 | Applicant | |
| WO-2004/035752(A2) | 2004-04-01 | Applicant | |
| WO-2004/063351(A2) | 2004-07-01 | Applicant | |
| WO-2004/063963(A2) | 2004-07-01 | Applicant | |
| WO-2004/074455(A2) | 2004-09-01 | Applicant | |
| WO-2004/074499(A2) | 2004-09-01 | Applicant | |
| WO-2004/099249(A2) | 2004-11-01 | Applicant | |
| WO-2005/003175(A2) | 2005-01-01 | Applicant | |
| WO-2005/018572(A2) | 2005-03-01 | Applicant | |
| WO-2005/040217(A2) | 2005-05-01 | Applicant | |
| WO-2005/056606(A2) | 2005-06-01 | Applicant | |
| WO-2005/056759(A2) | 2005-06-01 | Applicant | |
| WO-2005/070963(A1) | 2005-08-01 | Applicant | |
| WO-2005/077981(A2) | 2005-08-01 | Applicant | |
| WO-2005/115452(A2) | 2005-12-01 | Applicant | |
| WO-2006/019447(A1) | 2006-02-01 | Applicant | |
| WO-2006/020114(A2) | 2006-02-01 | Applicant | |
| WO-2006/031370(A2) | 2006-03-01 | Applicant | |
| WO-2006/033702(A2) | 2006-03-01 | Applicant | |
| WO-2007/059332(A2) | 2007-05-01 | Applicant | |
| WO2007/100289(A2) | 2007-09-01 | Applicant |
Non-Patent Literature (86)
- Attwood T. Science 2000; 290:471-47.Examiner
- Skolnick et al., Trends in Biotech. 2000; 18(1):34-39.Examiner
- Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for Application No. PCT/US2004/27476, dated Jan. 20, 2006.Applicant
- Shields, Robert L. et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR,” The Journal of Biological Chemistry, vol. 276(9):6591-6604 (2001).Applicant
- Sondermann, Peter et al., “The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex,” Nature, vol. 406:267-273 (2000).Applicant
- Tao, Mi-Hua et al., “Studies of Aglycosylated Chimeric Mouse-Human IgG, Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,” The Journal of Immunology, vol. 143(8):2595-2601 (1989).Applicant
- Supplementary European Search Report for Application No. 04782045.1, dated May 7, 2009.Applicant
- Armour, Kathryn L. et al., “Differential binding to human FcyRIIa and FcyRIIb receptors by human IgG wildtype and mutant antibodies,” Molecular Immunology, vol. 40:585-593 (2003).Applicant
- Armour, Kathryn L. et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities,” Eur. J. Immunol., vol. 29:2613-2624 (1999).Applicant
- Bastida-Corcuera, F.D. et al., “Differential complement activation by bovine IgG2 allotypes,” Veterinary Immunology and Immunopathology, vol. 71:115-123 (1999).Applicant
- Boyd, P.N. et al., “The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of campath-1H,” Molecular Immunology, vol. 32(17/18):1311-1318 (1995).Applicant
- Brekke, Ole Henrik et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,” Eur. J. Immunol., vol. 24:2542-2547 (1994).Applicant
- Burton, Dennis R., “Immunoglobulin G: Functional Sites,” Molecular Immunology, vol. 22(3):161-206 (1985).Applicant
- Burton, D.R. et al., “The C1q receptor site on immunoglobulin G,” Nature, vol. 288:338-344 (1980).Applicant
- Canfield, Stephen M. et al., “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region,” J. Exp. Med., vol. 173:1483-1491 (1991).Applicant
- Caron, Philip C. et al., “Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies,” J. Exp. Med., vol. 176:1191-1195 (1992).Applicant
- Chan, Lisa A. et al., “Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions,” Molecular Immunology, vol. 41:527-538 (2004).Applicant
- Chappel, M. Suzanne et al., “Identification of the Fey receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies,” Proc. Natl. Acad. Sci. USA, vol. 88:9036-9040 (1991).Applicant
- Chirino, Arthur J. et al., “Minimizing the immunogenicity of protein therapeutics,” Drug Discovery Today, vol. 9(2):82-90 (2004).Applicant
- Cole, Michael S. et al., “HuM291, A Humanized Anti-CD3 Antibody, is Immunosuppressive to T Cells While Exhibiting Reduced Mitogenicity in Vitro,” Transplantation, vol. 68(4):563-571 (1999).Applicant
- Cole, Michael S. et al., “Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells,” The Journal of Immunology, vol. 159:3613-3621 (1997).Applicant
- Daeron, Marc, “Fc Receptor Biology,” Annu. Rev. Immunol., vol. 15:203-234 (1997).Applicant
- Dahiyat, Bassil I. et al., “Protein design automation,” Protein Science, vol. 5:895-903 (1996).Applicant
- Dall'Acqua, William F. et al., “Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region,” The Journal of Immunology, vol. 177:1129-1138 (2006).Applicant
- Dorai, Haimanti et al., “Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function,” Hybridoma, vol. 10(2):211-217 (1991).Applicant
- Duncan, Alexander R. et al., “Localization of the binding site for the human high-affinity Fc receptor on IgG,” Nature, vol. 332:563-564 (1988).Applicant
- Duncan, Alexander R. et al., “The binding site for C1q on IgG,” Nature, vol. 332:738-740 (1988).Applicant
- Elster, Eric A. et al., “Treatment with the Humanized CD154-Specific Monoclonal Antibody, hu5C8, Prevents Acute Rejection of Primary Skin Allografts in Nonhuman Primates,” Transplantation, vol. 72(9):1473-1478 (2001).Applicant
- Friend, P.J. et al., “Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection,” Transplantation, vol. 68(11):1632-1637 (1999).Applicant
- Gergely, J. et al., “Fc receptors on lymphocytes and K cells,” Biochemical Society Transactions, vol. 12(5):739-743 (1984).Applicant
- Gillies, Stephen D. et al., “Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors,” Cancer Research, vol. 59:2159-2166 (1999).Applicant
- Graddis, T.J. et al., “Designing Proteins That Work Using Recombinant Technologies,” Current Pharmaceutical Biotechnology, vol. 3:285-297 (2002).Applicant
- Hand, Patricia Horan et al., “Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant,” Cancer lmmunol. lmmunother., vol. 35:165-174 (1992).Applicant
- Hayes, Robert J. et al., “Combining computational and experimental screening for rapid optimization of protein properties,” PNAS, vol. 99(25):15926-15931 (2002).Applicant
- Hobbs, S.M. et al., “Interaction of Aglycosyl Immunoglobulins with the IgG Fc Transport Receptor from Neonatal Rat Gut: Comparison of Deglycosylation by Tunicamycin Treatment and Genetic Engineering,” Molecular Immunology, vol. 29(7/8):949-956 (1992).Applicant
- Hsu, Tsu-An et al., “Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in Trichoplusia ni Cells,” The Journal of Biological Chemistry, vol. 272(14):9062-9070 (1997).Applicant
- Idusogie, Esohe E. et al., “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc,” The Journal of Immunology, vol. 164:4178-4184 (2000).Applicant
- Isaacs, John D. et al., “Therapy with Monoclonal Antibodies, An in Vivo Model for the Assessment of Therapeutic Potential,” The Journal of Immunology, vol. 148(10):3062-3071 (1992).Applicant
- Jefferis, R. et al., “Glycosylation of antibody molecules: structural and functional significance,” Chem. Immunol., vol. 65:111-128 (1997).Applicant
- Kato, K. et al., “Analysis of IgG-FcγR Interactions in Solution: Mapping of the FcγR Binding Site and Evidence for a Conformational Change Occuring in the Fc Region,” Immunology, Letters, vol. 73(2-3) No. 409 (2000).Applicant
- Klein, Michel et al., “Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region,” Proc. Natl. Acad. Sci. USA, vol. 78(1):524-528 (1981).Applicant
- Kunkel, Thomas A., “Rapid and efficient site-specific mutageneis without phenotypic selection,” Proc. Natl. Acad. Sci. USA, vol. 82:488-492 (1985).Applicant
- Lazar, Greg A. et al., “Engineered antibody Fc variants with enhanced effector function,” PNAS, vol. 103(11):4005-4010 (2006).Applicant
- Leader, K.A. et al., “Functional interactions of aglycosylated monoclonal anti-D with FcγRI+ and FcyRIII+ cells,” Immunology, vol. 72:481-485 (1991).Applicant
- Leatherbarrow, Robin J. et al., “Effector Functions of a Monoclonal Aglycosylated Mouse IgG2a: Binding and Activation of Complement Component C1 and Interaction with Human Monocyte Fc Receptor,” Molecular Immunology, vol. 22(4):407-415 (1985).Applicant
- Leatherbarrow, Robin J. et al., “The effect of aglycosylation on the binding of mouse IgG to staphylococcal protein A,” FEBS, vol. 164(2):227-230 (1983).Applicant
- Liu, Alvin Y. et al., “Production of a Mouse-human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity,” The Journal of Immunology, vol. 139(10):3521-3526 (1987).Applicant
- Lund John et al., “A Protein Structural Change in Aglycosylated IgG3 Correlates with Loss of huFcγR1 and huFcγRIII Binding and/or Activation,” Molecular Immunology, vol. 27(11):1145-1153 (1990).Applicant
- Lund John et al., “Human FcγRI and FcγRll Interact with Distinct but Overlapping Sites on Human IgG,” The Journal of Immunology, vol. 147(8):2657-2662 (1991).Applicant
- Morrison, Sherie L. et al., “Variable Region Domain Exchange Influences the Functional Properties of IgG,” The Journal of Immunology, vol. 160:2802-2808 (1998).Applicant
- Marzocchi-Machado, C.M. et al., “The Influence of Antibody Functional Affinity on the Effector Functions Involved in the Clearance of Circulating Immune Complexes Anti-BSA IgG/BSA,” Immunological Investigations, vol. 28(2&3):89-101 (1999).Applicant
- Mueller, John P. et al., “Humanized Porcine VCAM-Specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells,” Molecular Immunology, vol. 34(6):441-452 (1997).Applicant
- Natsume, Akito et al., “Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities,” Cancer Research, vol. 68(10):3863-3872 (2008).Applicant
- Newkirk, M.M. et al., “Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice,” Clin. Exp. Immunol., vol. 106:259-264 (1996).Applicant
- Nose, Masato et al., “Biological significance of carbohydrate chains on monoclonal antibodies,” Proc. Natl. Acad. Sci. USA, vol. 80:6632-6636 (1983).Applicant
- Patel, Thakor P. et al., “Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody,” Biochem. J., vol. 285:839-845 (1992).Applicant
- Pendley, Charles et al., “Immunogenicity of therapeutic monoclonal antibodies,” Current Opinion in Molecular Therapeutics, vol. 5(2):172-179 (2003).Applicant
- Pound, John D. et al., “Aglycosylated Chimaeric Human IgG3 Can Trigger the Human Phagocyte Respiratory Burst,” Molecular Immunology, vol. 30(3):233-241 (1993).Applicant
- Radaev, Sergei et al., “The Structure of a Human Type III Fcγ Receptor in Complex with Fc,” The Journal of Biological Chemistry, vol. 276(19):16469-16477 (2001).Applicant
- Raju, T. Shantha, “Glycosylation Variations with Expression Systems and Their Impact on Biological Activity of Therapeutic Immunoglobulins,” BioProcess International, 44-53 (2003).Applicant
- Raju, T. Shantha et al., “Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics,” Glycobiology, vol. 10(5):477-486 (2000).Applicant
- Ravetch, Jeffrey V. et al., “Fc Receptors,” Annu. Rev. Immunol., vol. 9:457-492 (1991).Applicant
- Sármay, G. et al., “Ligand Inhibition Studies on the Role of Fc Receptors in Antibody-Dependent Cell-mediated Cytotoxicity,” Molecular Immunology, vol. 21(1):43-51 (1984).Applicant
- Shitara, Kenya et al., “A new vector for the high level expression of chimeric antibodies in myeloma cells,” Journal of Immunological Methods, vol. 167:271-278 (1994).Applicant
- Shields, Robert L. et al., “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity,” The Journal of Biological Chemistry, vol. 277(30):26733-26740 (2002).Applicant
- Shinkawa, Toyohide et al., “The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity,” The Journal of Biological Chemistry, vol. 278(5):3466-3473 (2003).Applicant
- Shopes, Bob, “A Genetically Engineered Human IgG Mutant with Enhanced Cytolytic Activity,” The Journal of Immunology, vol. 148(9):2918-2922 (1992).Applicant
- Simmons, Laura C. et al., “Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies,” Journal of Immunological Methods, vol. 263:133-147 (2002).Applicant
- Sondermann, P. et al., “Mediation and Modulation of Antibody Function,” Biochemical Society Transactions, vol. 30:481-486 (2002).Applicant
- Tamm, Anu et al., “IgG Binding Sites on Human Fcγ Receptors,” Intern. Rev. Immunol., vol. 16:57-85 (1997).Applicant
- Tao, Mi-Hua et al., “Structural Features of Human Immunoglobulin G that Determine Isotype-specific Differences in Complement Activation,” J. Exp. Med., vol. 178:661-667 (1993).Applicant
- Trebak, Mohamed et al., “Efficient laboratory-scale production of monoclonal antibodies using membrane-based high-density cell culture technology,” Journal of Immunological Methods, vol. 230:59-70 (1999).Applicant
- Umaña, Pablo et al., “Engineered glycoforrns of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity,” Nature Biotechnology, vol. 17:176-180 (1999).Applicant
- Waldmann, Herman, “The new immunosuppressive: just kill the T cell,” Nature Medicine, vol. 9(10):1259-1260 (2003).Applicant
- Valerius, Thomas et al., “FcαRl (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy,” Blood, vol. 90(11):4485-4492 (1997).Applicant
- Vitetta, Ellen S. et al., “Considering Therapeutic Antibodies,” Science, vol. 313:308-309 (2006).Applicant
- Walker, Matthew R. et al., “Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcγRl and/or RcγRll receptors,” Biochem. J., vol. 259:347-353 (1989).Applicant
- Ward, E.S. et al., “The effector functions of immunoglobulins: implications for therapy,” Therapeutic Immunology, vol. 2:77-94 (1995).Applicant
- Williams, Ralph C. Jr. et al., “Studies of Biologic and Serologic Activities of Rabbit-IgG Antibody Depleted of Carbohydrate Residues,” The Journal of Immunology, vol. 111(6):1690-1698 (1973).Applicant
- W.H.O., “Review of the notation for the allotypic and related markers of human immunoglobulins,” Eur. J. Immunol., vol. 6:599-601 (1976).Applicant
- W.H.O., “Review of the Notation for the Allotypic and Related Markers for Human Immunoglobulins,” Journal of Immunogenetics, vol. 3:357-362 (1976).Applicant
- Winkelhake, Jeffrey L. et al., “Aglycosylantibody, Effects of Exoglycosidase Treatments on Autochthonous Antibody Survival Time in the Circulation,” The Journal of Biological Chemistry, vol. 251(4):1074-1080 (1976).Applicant
- Woof, J.M. et al., “Localisation of the Monocyte-binding Region of Human Immunoglobulin G,” Molecular Immunology, vol. 23(3):319-330 (1986).Applicant
- Wright, Ann et al., “Effect of Altered CH2-associated Carbohydrate Structure on the Functional Properties and in Vivo Fate of Chimeric Mouse-Human Immunoglobulin G1,” J. Exp. Med., vol. 180:1087-1096 (1994).Applicant
- Yamane-Ohnuki, Naoko et al., “Establishment of FUT8 Knockout Chinese Hamster Ovary Cells: An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies With Enhanced Antibody-Dependent Cellular Cytotoxicity,” Biotechnology and Bioengineering, vol. 87(5):614-622 (2004).Applicant
- European Office Action for Application No. 04782045, dated Dec. 30, 2009.Applicant